Judith Bovée
Hoogleraar Pathologie, in het bijzonder de pathologie van bot- en wekedelentumoren
- Naam
- Prof.dr. J.V.M.G. Bovée
- Telefoon
- +31 71 526 9111
- j.v.m.g.bovee@lumc.nl
- ORCID iD
- 0000-0003-1155-0481
Judith V.M.G. Bovée is patholoog op de afdeling pathologie, LUMC, met als voornaamste aandachtsgebied bot- en wekedelentumoren. Zij combineert de patiëntenzorg met onderzoek, en haar werk werd in 2017 bekroond met een VICI-beurs om betere modellen te ontwikkelen om te komen tot personalized medicine voor patiënten met sarcomen.
Judith V.M.G. Bovée is patholoog op de afdeling pathologie, LUMC, met als voornaamste aandachtsgebied bot- en wekedelentumoren. Zij combineert de patiëntenzorg met onderzoek, en haar werk werd in 2017 bekroond met een VICI-beurs om betere modellen te ontwikkelen om te komen tot personalized medicine voor patiënten met sarcomen.
Onderzoek naar tumoren
Haar onderzoek richt zich op het ophelderen van de ontstaansmechanismen van goedaardige en kwaadaardige tumoren van het skelet en de wekedelen. Vervolgens onderzoekt haar groep niet alleen of de afwijkingen die leiden tot het ontstaan van de tumor gebruikt kunnen worden voor verbetering van de diagnostiek, maar ook of deze gebruikt kunnen worden voor aanvullende behandelingsmogelijkheden.
Wetenschappelijke carrière
Judith Bovée behaalde in 1997 haar artsexamen, waarna zij startte met haar promotieonderzoek bij Prof. P.C.W. Hogendoorn. Zij promoveerde in 2000 cum laude op het proefschrift 'A molecular genetic characterisation of cartilaginous tumors'. Na haar opleiding tot medisch specialist op de afdeling pathologie van het LUMC werd zij in 2003 geregistreerd als patholoog. Sindsdien werkt zij als staflid op de afdeling pathologie, LUMC, alwaar zij in 2013 werd benoemd tot hoogleraar. De titel van haar oratie luidt “Moleculen, Mechanismen, Maatwerk”. Zij is tevens nauw betrokken bij de moleculaire diagnostiek waarvoor zij in 2013 werd geregistreerd als klinisch moleculair bioloog in de pathologie.
Judith Bovée is, onder andere, referentie patholoog voor de EORTC en de Nederlandse Commissie voor Beentumoren, zij is bestuurslid (geweest) van diverse medische adviesraden van patiëntenverenigingen (bijvoorbeeld sarcoma.nl) alsmede van wetenschappelijke verenigingen (bijvoorbeeld “Connective Tissue Oncology Society”) en zij is lid van de “editorial board” van diverse tijdschriften (bijvoorbeeld “Laboratory Investigation”). Zij neemt deel aan diverse internationale consortia (bijvoorbeeld euroSARC) en heeft een belangrijke bijdrage geleverd aan de WHO classificatie voor bottumoren. Zij is auteur van >190 wetenschappelijke publicaties, en heeft >30 boekhoofdstukken geschreven. Zij is een veelgevraagd spreker op internationale congressen.
Prijzen en eervolle benoemingen
- 2017: VICI-laureaat, NWO
- 2015: “Boerhaave pluim”, voor excellente voordracht postacademisch onderwijs
- 2015: “Zeldzame engel” award; van de gezamenlijke patientenverenigingen voor zeldzame aandoeningen in Nederland
- 2007: Aspasia laureaat, NWO
- 2007: C.J. Kok prijs 2007, LUMC
- 2006: VIDI laureaat, NWO
- 2000: Dick Held Junior prijs 1999
- Koninklijke Nederlands Maatschappij ter bevordering van de Geneeskunde, Leiden
- 2000: New Investigators Award 2000 European Musculoskeletal Oncology Society
Meer informatie:
www.lumc.nl/bovee
Onderzoeksgroep
Volg Judith Bovee:
Academia | LinkedIn | Orcid | ResearchGate
Hoogleraar Pathologie, in het bijzonder de pathologie van bot- en wekedelentumoren
- Faculteit Geneeskunde
- Divisie 4
- Pathologie
- Miladinovic, V.; Kro,l A.D.G.; Bloem, J.L.; Bovee, J.V.M.G.; Lam, S.W.; Peul, W.C.; Navas Canete, A. & Verbist, B.M. (2024), Combining morphological and functional imaging parameters to diagnose primary bone neoplasms in the skull base, spine and sacrum, Skeletal Radiology.
- (2024), Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.
- Lipplaa, A.; Wal, R.J.P. van der; Krol, A.D.G.; Peul, W.C.; Bovée, J.V.M.G. & Gelderblom, H. (2024), Incidence and centralization of chordoma in the Netherlands, Cancer Epidemiology.
- Lam, S.W.; Silva, T.M.; Traast-Kooistra, J.; Briaire-de Bruijn, I.; Akker, B. van den; Bakker, P.A.C.; Lansu, J.; Haas, R.L.M. & Bovée, J.V.M.G. (2023), Histological response to radiotherapy is an early event in myxoid liposarcoma, Virchows Archiv 483(4): 487-495.
- Kalisvaart, G.M.; Berghe, T. van den; Grootjans, W.; Lejoly, M.; Huysse, W.C.J.; Bovée, J.V.M.G.; Creytens, D.; Gelderblom, H.; Speetjens, F.M.; Lapeire, L.; Sande, M.A.J. van de; Sys, G.; Geus-Oei, L.F. de; Verstraete, K.L. & Bloem, J.L. (2023), Evaluation of response to neoadjuvant chemotherapy in osteosarcoma using dynamic contrast-enhanced MRI, Skeletal Radiology 53.
- Ong, S.L.M.; Gomes, I.P.; Baelde, H.J.; Passador-Santos, F.; Andrade, B.A.B. de; Bruijn, I.H.B.D.; Cavalcante, I.L.; Schreuder, W.H.; Cleton-Jansen, A.M.; Cleven, A.H.G.; Szuhai, K.; Gomes, C.C. & Bovee, J.V.M.G. (2023), No NFATC2 fusion in simple bone cyst of the jaw, Histopathology 83(2): 326-329.
- Cleven, A.H.G.; Szuhai, K.; IJzendoorn, D.G.P. van; Groen, E.; Baelde, H.; Schreuder, W.H.; Briaire-de Bruijn, I.H.; Meeren, S.W. van der; Kleijwegt, M.C.; Furth, W.R.; Kroon, H.M.; Suurmeijer, A.J.H.; Savci-Heijink, D.C.; Baumhoer, D. & Bovee, J.V.M.G. (2023), Psammomatoid ossifying fibroma is defined by SATB2 rearrangement, Modern Pathology 36(1).
- Venneker, S. & Bovée, J.V.M.G. (2023), IDH Mutations in Chondrosarcoma: Case Closed or Not?, Cancers 15(14).
- Luk, S.J.; Schoppmeyer, R.; Ijsselsteijn, M.E.; Somarakis, A.; Acem, I.; Remst, D.F.G.; Cox, D.T.; Bergen, C.A.M. van; Briaire-de Bruijn, I.; Grönloh, M.L.B.; Meer, W.J. van der; Hawinkels, L.J.A.C.; Koning, R.I.; Bos, E.; Bovée, J.V.M.G.; Miranda, N.F.C.C. de; Szuhai, K.; Buul, J.D. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation, Cancer Immunology Research 11(11): 1480-1492.
- Tos, A.P.D.; Webster, F.; Agaimy, A.; Bovee, J.; Dickson, B.; Doyle, L.; Dry, S.; Gronchi, A.; Hameed, M.; Hemmings, C.; Liegl-Atzwanger, B.; Thway, K.; Wagner, A.J.; Wang, J.; Yoshida, A. & Fletcher, C. (2023), Datasets for reporting of soft-tissue sarcoma, Histopathology 82(5): 745-754.
- Bovée, J.V.M.G.; Webster, F.; Amary, F.; Baumhoer, D.; Bloem, J.L.; Bridge, J.A.; Cates, J.M.M.; Alava, E. de; Tos, A.P. dei; Jones, K.B.; Mahar, A.; Nielsen, G.P.; Righi, A.; Wagner, A.J.; Yoshida, A. & Fletcher, C.D.M. (2023), Datasets for the reporting of primary tumour in bone, Histopathology 82(4): 531-540.
- Palubeckaite, I.; Venneker, S.; Akker, B.E.W.M. van den; Briaire-de Bruijn, I. & Bovee, J.V.M.G. (2023), Does PARP inhibition sensitize chondrosarcoma cell lines to chemotherapy or radiotherapy?, Clinical Orthopaedics and Related Research 481(3): 608-619.
- Lam, S.W.; Silva, T.M. & Bovee, J.V.M.G. (2022), New molecular entities of soft tissue and bone tumors, Current Opinion in Oncology 34(4): 354-361.
- Bovee, J.V.M.G.; Webster, F.; Amary, F.; Baumhoer, D.; Bloem, J.L.; Bridge, J.A.; Cates, J.M.M.; Alava, E. de; Tos, A.P. dei; Jones, K.B.; Mahar, A.; Nielsen, G.P.; Righi, A.; Wagner, A.J.; Yoshida, A. & Fletcher, C.D.M. (2022), Datasets for the reporting of primary tumour in bone, Histopathology 82(4).
- Stacchiotti, S.; Frezza, A.M.; Demetri, G.D.; Blay, J.Y.; Bajpai, J.; Baldi, G.G.; Baldini, E.H.; Benjamin, R.S.; Bonvalot, S.; Bovee, J.V.M.G.; Callegaro, D.; Casali, P.G.; D'Angelo, S.P.; Davis, E.J.; Tos, A.P. dei; Demicco, E.G.; Desai, J.; Dileo, P.; Eriksson, M.; Gelderblom, H.; George, S.; Gladdy, R.A.; Gounder, M.M.; Gupta, A.A.; Haas, R.; Hayes, A.; Hohenberger, P.; Jones, K.B.; Jones, R.L.; Kasper, B.; Kawai, A.; Kirsch, D.G.; Kleinerman, E.S.; Cesne, A. le; Maestro, R.; Broto, J.M.; Maki, R.G.; Miah, A.B.; Palmerini, E.; Patel, S.R.; Raut, C.P.; Razak, A.R.A.; Reed, D.R.; Rutkowski, P.; Sanfilippo, R.G.; Sbaraglia, M.; Schaefer, I.M.; Strauss, D.C.; Strauss, S.J.; Tap, W.D.; Thomas, D.M.; Trama, A.; Trent, J.C.; Graaf, W.T.A. van der; Houdt, W.J. van; Mehren, M. von; Wilky, B.A.; Fletcher, C.D.M.; Gronchi, A.; Miceli, R. & Wagner, A.J. (2022), Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments, Cancer Treatment Reviews 110.
- Cleven, A.H.G.; Schreuder, W.H.; Groen, E.; Lange, J. de; Briaire-de Bruijn, I.H. & Bovee, J.V.M.G. (2022), Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours, Virchows Archiv 481(4): 671-675.
- Ameline, B.; Nathrath, M.; Nord, K.H.; Flon, F.H. de; Bovee, J.V.M.G.; Krieg, A.H.; Holler, S.; Hench, J. & Baumhoer, D. (2022), Methylation and copy number profiling , Modern Pathology 35(9): 1204-1211.
- Koch, R.; Gelderblom, H.; Haveman, L.; Brichard, B.; Jurgens, H.; Cyprova, S.; Berg, H. van den; Hassenpflug, W.; Raciborska, A.; Ek, T.; Baumhoer, D.; Egerer, G.; Eich, H.T.; Renard, M.; Hauser, P.; Burdach, S.; Bovee, J.; Bonar, F.; Reichardt, P.; Kruseova, J.; Hardes, J.; Kuhne, T.; Kessler, T.; Collaud, S.; Bernkopf, M.; Butterfass-Bahloul, T.; Dhooge, C.; Bauer, S.; Kiss, J.; Paulussen, M.; Hong, A.; Ranft, A.; Timmermann, B.; Rascon, J.; Vieth, V.; Kanerva, J.; Faldum, A.; Metzler, M.; Hartmann, W.; Hjorth, L.; Bhadri, V. & Dirksen, U. (2022), High-dose treosulfan and melphalan as consolidation therapy versus standard therapy for high-risk (metastatic) Ewing Sarcoma, Journal of Clinical Oncology 40(21): 2307-+.
- Weeda, Y.A.; Kalisvaart, G.M.; Velden, F.H.P. van; Gelderblom, H.; Molen, A.J. van der; Bovee, J.V.M.G.; Hage, J.A. van der; Grootjans, W. & Geus-Oei, L.F. de (2022), Early Prediction and Monitoring of Treatment Response in Gastrointestinal Stromal Tumors by Means of Imaging: A Systematic Review, Diagnostics 12(11).
- Heijden, L. van der; Lipplaa, A.; Langevelde, K. van; Bovee, J.V.M.G.; Sande, M.A.J. van de & Gelderblom, H. (2022), Updated concepts in treatment of giant cell tumor of bone, Current Opinion in Oncology 34(4): 371-378.
- Georgiesh, T.; Aggerholm-Pedersen, N.; Schoffski, P.; Zhang, Y.F.; Napolitano, A.; Bovee, J.V.M.G.; Hjelle, A.; Tang, G.; Spalek, M.; Nannini, M.; Swanson, D.; Baad-Hansen, T.; Sciot, R.; Hesla, A.C.; Huang, P.; Dorleijn, D.; Haugland, H.K.; Lacambra, M.; Skoczylas, J.; Pantaleo, M.A.; Haas, R.L.; Meza-Zepeda, L.A.; Haller, F.; Czarnecka, A.M.; Loong, H.; Jebsen, N.L.; Sande, M. van de; Jones, R.L.; Haglund, F.; Timmermans, I.; Safwat, A.; Bjerkehagen, B. & Boye, K. (2022), Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour, British Journal of Cancer 127(10): 1793-1798.
- Bonvalot, S.; Rutkowski, P.L.; Thariat, J.; Carrere, S.; Ducassou, A.; Sunyach, M.P.; Agoston, P.; Hong, A.M.; Mervoyer, A.; Rastrelli, M.; Moreno, V.; Li, R.K.; Tiangco, B.J.; Herra, A.C.; Gronchi, A.; Sy-Ortin, T.; Hohenberger, P.; Baere, T. de; Cesne, A. le; Helfre, S.; Saada-Bouzid, E.; Anghel, R.M.; Kantor, G.; Montero, A.; Loong, H.H.; Verges, R.; Kacso, G.; Austen, L.; Servois, V.F.; Wardelmann, E.; Dimitriu, M.; Said, P.; Lazar, A.J.; Bovee, J.V.M.G.; Pechoux, C. le & Papai, Z. (2022), Final safety andhHealth-related quality of lIfe results of the phase 2/3 Act.In.Sarc study with preoperative NBTXR3 plus radiation therapy versus radiation therapy in locally advanced soft-tissue sarcoma, International Journal of Radiation Oncology - Biology - Physics 114(3): 422-432.
- Toland, A.M.S.; Lam, S.W.; Varma, S.; Wang, A.H.; Howitt, B.E.; Kunder, C.A.; Kerr, D.A.; Szuhai, K.; Bovee, J.V.M.G. & Charville, G.W. (2022), GRM1 immunohistochemistry distinguishes chondromyxoid fibroma from its histologic mimics, The American Journal of Surgical Pathology 46(10): 1407-1414.
- Venneker, S.; Eenige, R. van; Kruisselbrink, A.B.; Palubeckaite, I.; Taliento, A.E.; Briaire-de Bruijn, I.H.; Hogendoorn, P.C.W.; Sande, M.A.J. van de; Gelderblom, H.; Mei, H.L.; Bovee, J.V.M.G. & Szuhai, K. (2022), Histone deacetylase inhibitors as a therapeutic strategy to eliminate neoplastic "stromal" cells from giant cell tumors of bone, Cancers 14(19).
- Haas, R.; Stelmes, J.J.; Zaffaroni, F.; Sauve, N.; Clementel, E.; Bar-Deroma, R.; Pechoux, C. le; Litiere, S.; Marreaud, S.; Alyamani, N.; Andratschke, N.H.J.; Sangalli, C.; Chung, P.W.; Miah, A.; Hurkmans, C.; Gronchi, A.; Bovee, J.V.M.G.; Gelderblom, H.; Kasper, B.; Weber, D.C. & Bonvalot, S. (2022), Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas, Cancer 128(14): 2796-2805.
- Ong, S.L.M.; Baelde, H.J.; IJzendoorn, D.G.P. van; Bovee, J.V.M.G. & Szuhai, K. (2022), Identification of stable housekeeping genes for induced pluripotent stem cells and -derived endothelial cells for drug testing, Scientific Reports 12(1).
- IJzendoorn, D.G.P. van; Matusiak, M.; Charville, G.W.; Spierenburg, G.; Varma, S.; Colburg, D.R.C.; Sande, M.A.J. van de; Langevelde, K. van; Mohler, D.G.; Ganjoo, K.N.; Bui, N.Q.; Avedian, R.S.; Bovee, J.V.M.G.; Steffner, R.; West, R.B. & Rijn, M. van de (2022), Interactions in CSF1-Driven tenosynovial giant cell tumors, Clinical Cancer Research 28(22): 4934-4946.
- Spierenburg, G.; Heijden, L. van der; Langevelde, K. van; Szuhai, K.; Bovee, J.V.G.M.; Sande, M.A.J. van de & Gelderblom, H. (2022), Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches, Expert Opinion on Therapeutic Targets 26(4): 333-345.
- Hondelink, L.M.; Schrader, A.M.R.; Aghmuni, G.A.; Solleveld-Westerink, N.; Cleton-Jansen, A.M.; Egmond, D. van; Boot, A.; Ouahoud, S.; Khalifa, M.N.; Lam, S.W.; Morreau, H.; Bovee, J.V.M.G.; Wezel, T. van & Cohen, D. (2022), The sensitivity of pan-TRK immunohistochemistry in solid tumours, European Journal of Cancer 173: 229-237.
- Lansu, J.; Bovee, J.V.M.G.; Braam, P.; , H. van boven; Flucke, U.; Bonenkamp, J.J.; Miah, A.B.; Zaidi, S.H.; Thway, K.; Bruland, O.S.; Baldini, E.H.; Jebsen, N.L.; Scholten, A.N.; Ende, P.L.A. van den; Krol, A.D.G.; Ubbels, J.F.; Hage, J.A. van der; Werkhoven, E. van; Klomp, H.M.; Graaf, W.T.A. van der; Coevorden, F. van; Schrage, Y.; Houdt, W.J. van & Haas, R.L. (2021), Dose reduction of preoperative radiotherapy in myxoid liposarcoma, JAMA Oncology 7(1).
- Franceschini, N.; Gaeta, R.; Krimpenfort, P.; Briaire-de Bruijn, I.; Kruisselbrink, A.B.; Szuhai, K.; Cleton-Jansen, A.M.; Bovee, J.V.M.G. & PalubeckaiteQ, L. (2021), A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target, Laboratory Investigation.
- Dermawan, J.K.; Azzato, E.M.; Billings, S.D.; Fritchie, K.J.; Aubert, S.; Bahrami, A.; Barisella, M.; Baumhoer, D.; Blum, V.; Bode, B.; Aesif, S.W.; Bovee, J.V.M.G.; Dickson, B.C.; Hout, M. van den; Lucas, D.R.; Moch, H.; Oaxaca, G.; Righi, A.; Sciot, R.; Sumathi, V.; Yoshida, A. & Rubin, B.P. (2021), YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases, Modern Pathology 34(12): 2211-2221.
- Stacchiotti, S.; Frezza, A.M.; Blay, J.Y.; Baldini, E.H.; Bonvalot, S.; Bovee, J.V.M.G.; Callegaro, D.; Casali, P.G.; Chiang, R.C.J.; Demetri, G.D.; Demicco, E.G.; Desai, J.; Eriksson, M.; Gelderblom, H.; George, S.; Gounder, M.M.; Gronchi, A.; Gupta, A.; Haas, R.L.; Hayes-Jardon, A.; Hohenberger, P.; Jones, K.B.; Jones, R.L.; Kasper, B.; Kawai, A.; Kirsch, D.G.; Kleinerman, E.S.; Cesne, A. le; Lim, J.; Lopez, M.D.C.; Maestro, R.; Marcos-Gragera, R.; Broto, J.M.; Matsuda, T.; Mir, O.; Patel, S.R.; Raut, C.P.; Razak, A.R.A.; Reed, D.R.; Rutkowski, P.; Sanfilippo, R.G.; Sbaraglia, M.; Schaefer, I.M.; Strauss, D.C.; Hall, K.S.; Tap, W.D.; Thomas, D.M.; Graaf, W.T.A. van der; Houdt, W.J. van; Visser, O.; Mehren, M. von; Wagner, A.J.; Wilky, B.A.; Won, Y.J.; Fletcher, C.D.M.; Tos, A.P. dei & Trama, A. (2021), Ultra-rare sarcomas, Cancer 127(16): 2934-2942.
- Franceschini, N.; Verbruggen, B.; Tryfonidou, M.A.; Kruisselbrink, A.B.; Baelde, H.; Visser, K.E. de; Szuhai, K.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2021), Transformed canine and murine mesenchymal stem cells as a model for sarcoma with complex genomics, Cancers 13(5).
- Franceschini, N.; Oosting, J.; Tamsma, M.; Niessen, B.; Briaire-de Bruijn, I.; Akker, B. van den; Kruisselbrink, A.B.; Palubeckaite, I.; Bovee, J.V.M.G. & Cleton-Jansen, A.M. (2021), Targeting the NAD salvage synthesis pathway as a novel therapeutic strategy for osteosarcomas with low NAPRT expression, International Journal of Molecular Sciences 22(12).
- Kroonen, J.S.; Kruisselbrink, A.B.; Briaire-de Bruijn, I.H.; Olaofe, O.O.; Bovee, J.V.M.G. & Vertegaal, A.C.O. (2021), SUMOylation is associated with aggressive behavior in chondrosarcoma of bone, Cancers 13(15).
- Gronchi, A.; Miah, A.B.; DeiTos, A.P.; Abecassis, N.; Bajpai, J.; Bauer, S.; Biagini, R.; Bielack, S.; Blay, J.Y.; Bolle, S.; Bonvalot, S.; Boukovinas, I.; Bovee, J.V.M.G.; Boye, K.; Brennan, B.; Brodowicz, T.; Buonadonna, A.; DeAlava, E.; Muro, X.G. del; Dufresne, A.; Eriksson, M.; Fagioli, F.; Fedenko, A.; Ferraresi, V.; Ferrari, A.; Frezza, A.M.; Gasperoni, S.; Gelderblom, H.; Gouin, F.; Grignani, G.; Haas, R.; Hassan, A.B.; Hecker-Nolting, S.; Hindi, N.; Hohenberger, P.; Joensuu, H.; Jones, R.L.; Jungels, C.; Jutte, P.; Kager, L.; Kasper, B.; Kawai, A.; Kopeckova, K.; Krakorova, D.A.; Cesne, A. le; LeGrange, F.; Legius, E.; Leithner, A.; Lopez-Pousa, A.; Martin-Broto, J.; Merimsky, O.; Messiou, C.; Mir, O.; Montemurro, M.; Morland, B.; Morosi, C.; Palmerini, E.; Pantaleo, M.A.; Piana, R.; Piperno-Neumann, S.; Reichardt, P.; Rutkowski, P.; Safwat, A.A.; Sangalli, C.; Sbaraglia, M.; Scheipl, S.; Schoffski, P.; Sleijfer, S.; Strauss, D.; Strauss, S.; SundbyHall, K.; Trama, A.; Unk, M.; VandeSande, M.A.J.; VanderGraaf, W.T.A.; Houdt, W.J. van; Frebourg, T.; Casali, P.G.; Stacchiotti, S.; ESMO Guidelines Comm; EURACAN & GENTURIS (2021), Soft tissue and visceral sarcomas, Annals of Oncology 32(11): 1348-1365.
- Meekeren, M. van; Bovee, J.V.M.G.; Coevorden, F. van; Houdt, W. van; Schrage, Y.; Koenen, A.M.; Miah, A.B.; Zaidi, S.; Hayes, A.J.; Thway, K.; Krol, S.; Fiocco, M.; Gelderblom, H.; Steeghs, N. & Haas, R.L. (2021), Revision of: a phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma, Acta Oncologica 60(12): 1557-1564.
- Schoffski, P.; Toulmonde, M.; Estival, A.; Marquina, G.; Dudzisz-Sledz, M.; Brahmi, M.; Steeghs, N.; Karavasilis, V.; Haan, J. de; Wozniak, A.; Cousin, S.; Domenech, M.; Bovee, J.V.M.G.; Charon-Barra, C.; Marreaud, S.; Litiere, S.; Meulemeester, L. de; Olungu, C. & Gelderblom, H. (2021), Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy, European Journal of Cancer 152: 26-40.
- Kalisvaart, G.M.; Grootjans, W.; Bovee, J.V.M.G.; Gelderblom, H.; Hage, J.A. van der; Sande, M.A.J. van de; Velden, F.H.P. van; Bloem, J.L. & Geus-Oei, L.F. de (2021), Prognostic value of quantitative [F-18]FDG-PET features in patients with metastases from soft tissue sarcoma, Diagnostics 11(12).
- Kalisvaart, G.M.; Bloem, J.L.; Bovee, J.V.M.G.; Sande, M.A.J. van de; Gelderblom, H.; Hage, J.A. van der; Hartgrink, H.H.; Krol, A.D.G.; Geus-Oei, L.F. de & Grootjans, W. (2021), Personalising sarcoma care using quantitative multimodality imaging for response assessment, Clinical Radiology 76(4).
- Lam, S.W.; Bruijn, I.H.B.D.; Wezel, T. van; Cleven, A.H.G.; Hogendoorn, P.C.W.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2021), NTRK fusions are extremely rare in bone tumours, Histopathology 79(5): 880-885.
- Tesileanu, C.M.S.; Vallentgoed, W.R.; Sanson, M.; Taal, W.; Clement, P.M.; Wick, W.; Brandes, A.A.; Baurain, J.F.; Chinot, O.L.; Wheeler, H.; Gill, S.; Griffin, M.; Rogers, L.; Ruda, R.; Weller, M.; McBain, C.; Reijneveld, J.; Enting, R.H.; Caparrotti, F.; Lesimple, T.; Clenton, S.; Gijtenbeek, A.; Lim, E.; Vos, F. de; Mulholland, P.J.; Taphoorn, M.J.B.; Heer, I. de; Hoogstrate, Y.; Wit, M. de; Boggiani, L.; Venneker, S.; Oosting, J.; Bovee, J.V.M.G.; Erridge, S.; Vogelbaum, M.A.; Nowak, A.K.; Mason, W.P.; Kros, J.M.; Wesseling, P.; Aldape, K.; Jenkins, R.B.; Dubbink, H.J.; Baumert, B.; Golfinopoulos, V.; Gorlia, T.; Bent, M. van den & French, P.J. (2021), Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations, Acta Neuropathologica 141(6): 945-957.
- Lam, S.W.; Kostine, M.; Miranda, N.F.C.C. de; Schoffski, P.; Lee, C.J.; Morreau, H. & Bovee, J.V.M.G. (2021), Mismatch repair deficiency is rare in bone and soft tissue tumors, Histopathology 79(4): 509-520.
- Haller, F.; Schlieben, L.D.; Ferrazzi, F.; Michal, M.; Stohr, R.; Moskalev, E.A.; Bieg, M.; Bovee, J.V.M.G.; Strobel, P.; Ishaque, N.; Grutzmann, R.; Meidenbauer, N.; Eils, R.; Wiemann, S.; Hartmann, A.; Michal, M. & Agaimy, A. (2021), Lipomatous Solitary Fibrous Tumors Harbor Rare NAB2-STAT6 Fusion Variants and Show Up-Regulation of the Gene PPARG, Encoding for a Regulator of Adipocyte Differentiation, The American Journal of Pathology 191(7): 1314-1324.
- Oost, S. van; Meijer, D.M.; Kuijjer, M.L.; Bovee, J.V.M.G. & Miranda, N.F.C.C. de (2021), Linking immunity with genomics in sarcomas: is genomic complexity an immunogenic trigger?, Biomedicines 9(8).
- Buffet, A.; Zhang, J.; Rebel, H.; Corssmit, E.P.M.; Jansen, J.C.; Hensen, E.F.; Bovee, J.V.M.G.; Morini, A.; Gimenez-Roqueplo, A.P.; Hes, F.J.; Devilee, P.; Favier, J. & Bayley, J.P. (2021), Germline DLST variants promote epigenetic modifications in pheochromocytoma-paraganglioma, The Journal of Clinical Endocrinology & Metabolism 106(2): 459-471.
- Ong, S.L.M.; Szuhai, K. & Bovee, J.V.M.G. (2021), Gene fusions in vascular tumors and their underlying molecular mechanisms, Expert Review of Molecular Diagnostics 21(9): 897-909.
- Groen, R.A.L. de; Eijk, R. van; Bohringer, S.; Wezel, T. van; Raghoo, R.; Ruano, D.; Jansen, P.M.; Briaire-De Bruijn, I.; Groot, F.A. de; Kleiverda, K.; Boome, L. te; Terpstra, V.; Levenga, H.; Nicolae, A.; Posthuma, E.F.M.; Focke-Snieders, I.; Hardi, L.; Hartog, W.C.E. den; Bohmer, L.H.; Hogendoorn, P.C.W.; Berg, A. van den; Diepstra, A.; Nijland, M.; Lugtenburg, P.J.; Kersten, M.J.; Pals, S.T.; Veelken, H.; Bovee, J.V.M.G.; Cleven, A.H.G. & Vermaat, J.S.P. (2021), Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype, Blood Advances 5(19): 3760-3775.
- Lam, S.W.; Cleven, A.H.G.; Briaire-de Bruijn, I.H.; Schreuder, W.H.; Kroon, H.M.; Savci-Heijink, D.C.; Suurmeijer, A.J.H.; Szuhai, K.; Bovee, J.V.M.G. & Baumhoer, D. (2021), FOS rearrangement and expression in cementoblastoma, The American Journal of Surgical Pathology 45(5): 690-693.
- Ong, S.L.M.; Lam, S.W.; Akker, B.E.W.M. van den; Kroon, H.M.; Bruijn, I.B.D.H.; Cleven, A.H.G.; Savci-Heijink, D.C.; Cleton-Jansen, A.M.; Baumhoer, D.; Szuhai, K. & Bovee, J.V.M.G. (2021), Expanding the spectrum of EWSR1-NFATC2-rearranged benign tumors a common genomic abnormality in vascular malformation/hemangioma and simple bone cyst, The American Journal of Surgical Pathology 45(12): 1669-1681.
- Stacchiotti, S.; Miah, A.B.; Frezza, A.M.; Messiou, C.; Morosi, C.; Caraceni, A.; Antonescu, C.R.; Bajpai, J.; Baldini, E.; Bauer, S.; Biagini, R.; Bielack, S.; Blay, J.Y.; Bonvalot, S.; Boukovinas, I.; Bovee, J.V.M.G.; Boye, K.; Brodowicz, T.; Callegaro, D.; Alava, E. de; Deoras-Sutliff, M.; Dufresne, A.; Eriksson, M.; Errani, C.; Fedenko, A.; Ferraresi, V.; Ferrari, A.; Fletcher, C.D.M.; Muro, X.G. del; Gelderblom, H.; Gladdy, R.A.; Gouin, F.; Grignani, G.; Gutkovich, J.; Haas, R.; Hindi, N.; Hohenberger, P.; Huang, P.; Joensuu, H.; Jones, R.L.; Jungels, C.; Kasper, B.; Kawai, A.; Cesne, A. le; Grange, F. le; Leithner, A.; Leonard, H.; Pousa, A.L.; Broto, J.M.; Merimsky, O.; Merriam, P.; Miceli, R.; Mir, O.; Molinari, M.; Montemurro, M.; Oldani, G.; Palmerini, E.; Pantaleo, M.A.; Patel, S.; Piperno-Neumann, S.; Raut, C.P.; Ravi, V.; Razak, A.R.A.; Reichardt, P.; Rubin, B.P.; Rutkowski, P.; Safwat, A.A.; Sangalli, C.; Sapisochin, G.; Sbaraglia, M.; Scheipl, S.; Schoffski, P.; Strauss, D.; Strauss, S.J.; Hall, K.S.; Tap, W.D.; Trama, A.; Tweddle, A.; Graaf, W.T.A. van der; Sande, M.A.J. van de; Houdt, W. van; Oortmerssen, G. van; Wagner, A.J.; Wartenberg, M.; Wood, J.; Zaffaroni, N.; Zimmermann, C.; Casali, P.G.; Tos, A.P. dei & Gronchi, A. (2021), Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts, ESMO Open 6(3).
- Haas, R.L.M.; Stelmes, J.J.; Zaffaroni, F.; Clementel, E.; Bar Deroma, R.; Pechoux, C. le; Litiere, S.; Marreaud, S.; Alyamani, N.; Andratschke, N.; Sangalli, C.; Chung, P.W.M.; Miah, A.; Hurkmans, C.; Gronchi, A.; Bovee, J.V.M.G.; Gelderblom, H.; Kasper, B.; Weber, D. & Bonvalot, S. (2021), Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: results from the 62092-22092 STRASS trial., Journal of Clinical Oncology 39(15).
- Lee, C.J.; Schoffski, P.; Modave, E.; Wezel, T. van; Boeckx, B.; Sufliarsky, J.; Gelderblom, H.; Blay, J.Y.; Debiec-Rychter, M.; Sciot, R.; Bovee, J.V.M.G.; Lambrechts, D. & Wozniak, A. (2021), Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib, Clinical Cancer Research 27(24): 6737-6748.
- Van Meekeren M, Fiocco M, Ho VKY, Bovée J, Gelderblom H & Haas RL (2021), Patterns of perioperative treatment and survival of localized, resected, intermediate- or high-grade soft tissue sarcoma, Sarcoma 2021: 9976122.
- Haas, R.L.; Floot, B.G.J.; Scholten, A.N.; Graaf, W.T.A. van der; Houdt, W. van; Schrage, Y.; Ven, M. van de; Bovee, J.V.M.G.; Coevorden, F. van & Vens, C. (2021), Cellular Radiosensitivity of Soft Tissue Sarcoma, Radiation Research 196(1): 23-30.
- Rijs, Z.; Shifai, A.N.; Bosma, S.E.; Kuppen, P.J.K.; Vahrmeijer, A.L.; Keereweer, S.; Bovee, J.V.M.G.; Sande, M.A.J. van de; Sier, C.E.M. & Driel, P.B.A.A. van (2021), Candidate biomarkers for specific intraoperative near-infrared imaging of soft tissue sarcomas: a systematic review, Cancers 13(3).
- Strauss, S.J.; Frezza, A.M.; Abecassis, N.; Bajpai, J.; Bauer, S.; Biagini, R.; Bielack, S.; Blay, J.Y.; Bolle, S.; Bonvalot, S.; Boukovinas, I.; Bovee, J.V.M.G.; Boye, K.; Brennan, B.; Brodowicz, T.; Buonadonna, A.; Alava, E. de; Tos, A.P. dei; Muro, X.G. del; Dufresne, A.; Eriksson, M.; Fagioli, F.; Fedenko, A.; Ferraresi, V.; Ferrari, A.; Gaspar, N.; Gasperoni, S.; Gelderblom, H.; Gouin, F.; Grignani, G.; Gronchi, A.; Haas, R.; Hassan, A.B.; Hecker-Nolting, S.; Hindi, N.; Hohenberger, P.; Joensuu, H.; Jones, R.L.; Jungels, C.; Jutte, P.; Kager, L.; Kasper, B.; Kawai, A.; Kopeckova, K.; Krakorova, D.A.; Cesne, A. le; Grange, F. le; Legius, E.; Leithner, A.; Pousa, A.L.; Martin-Broto, J.; Merimsky, O.; Messiou, C.; Miah, A.B.; Mir, O.; Montemurro, M.; Morland, B.; Morosi, C.; Palmerini, E.; Pantaleo, M.A.; Piana, R.; Piperno-Neumann, S.; Reichardt, P.; Rutkowski, P.; Safwat, A.A.; Sangalli, C.; Sbaraglia, M.; Scheipl, S.; Schoffski, P.; Sleijfer, S.; Strauss, D.; Hall, K.S.; Trama, A.; Unk, M.; Sande, M.A.J. van de; Graaf, W.T.A. van der; Houdt, W.J. van; Frebourg, T.; Ladenstein, R.; Casali, P.G.; Stacchiotti, S.; ESMO Guidelines Comm; EURACAN; GENTURIS & ERN PaedCan (2021), Bone sarcomas, Annals of Oncology 32(12): 1520-1536.
- Khurshed, M.; Molenaar, R.J.; Linde, M.E. van; Mathot, R.A.; Struys, E.A.; Wezel, T. van; Noorden, C.J.F. van; Klumpen, H.J.; Bovee, J.V.M.G. & Wilmink, J.W. (2021), A phase ib clinical trial of metformin and chloroquine in patients with IDH1-mutated solid tumors, Cancers 13(10).
- Demetri, G.D.; Antonescu, C.R.; Bjerkehagen, B.; Bovee, J.V.M.G.; Boye, K.; Chacon, M.; Tos, A.P. dei; Desai, J.; Fletcher, J.A.; Gelderblom, H.; George, S.; Gronchi, A.; Haas, R.L.; Hindi, N.; Hohenberger, P.; Joensuu, H.; Jones, R.L.; Judson, I.; Kang, Y.K.; Kawai, A.; Lazar, A.J.; Cesne, A. le; Maestro, R.; Maki, R.; Martin, J.; Patel, S.; Penault-Llorca, F.; Raut, C.P.; Rutkowski, P.; Safwat, A.; Sbaraglia, M.; Schaefer, I.M.; Shen, L.; Serrano, C.; Schoffski, P.; Stacchiotti, S.; Hall, K.S.; Tap, W.D.; Thomas, D.M.; Trent, J.; Valverde, C.; Graaf, W.T.A. van der; Mehren, M. von; Wagner, A.; Wardelmann, E.; Naito, Y.; Zalcberg, J. & Blay, J.Y. (2020), Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network, Annals of Oncology 31(11): 1506-1517.
- Venneker, S.; Kruisselbrink, A.B.; Baranski, Z.; Palubeckaite, I.; Briaire-de Bruijn, I.H.; Oosting, J.; French, P.J.; Danen, E.H.J. & Bovee, J.V.M.G. (2020), Beyond the influence of IDH mutations, Cancers 12(12).
- Roche, M.E.; Lin, Z.; Whitaker-Menezes, D.; Zhan, T.T.; Szuhai, K.; Bovee, J.V.M.G.; Abraham, J.A.; Jiang, W.; Martinez-Outschoorn, U. & Basu-Mallick, A. (2020), Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma, BBA - Molecular Basis of Disease 1866(12).
- Bloem, J.L.; Vriens, D.; Krol, A.D.G.; Ozdemir, M.; Sande, M.A.J. van de; Gelderblom, H.; Bovee, J.V.M.G.; Hage, J.A. van der & Noebauer-Huhmann, I.M. (2020), Therapy-Related Imaging Findings in Patients with Sarcoma, Seminars in Musculoskeletal Radiology 24(06): 676-691.
- Loarer, F. le; Cleven, A.H.G.; Bouvier, C.; Castex, M.P.; Romagosa, C.; Moreau, A.; Salas, S.; Bonhomme, B.; Gomez-Brouchet, A.; Laurent, C.; Guellec, S. le; Audard, V.; Giraud, A.; Ramos-Oliver, I.; Cleton-Jansen, A.M.; Savci-Heijink, D.C.; Kroon, H.M.; Baud, J.; Pissaloux, D.; Pierron, G.; Sherwood, A.; Coindre, J.M.; Bovee, J.V.M.G.; Larousserie, F. & Tirode, F. (2020), A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation, Modern Pathology 33(3): 404-419.
- Lam, S.W.; Cleven, A.H.G.; Kroon, H.M.; Briaire-de Bruijn, I.H.; Szuhai, K. & Bovee, J.V.M.G. (2020), Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma, Virchows Archiv 476(3): 455-463.
- Schutgens, E.M.; Picci, P.; Baumhoer, D.; Pollock, R.; Bovee, J.V.M.G.; Hogendoorn, P.C.W.; Dijkstra, P.D.S.; Rueten-Budde, A.J.; Jutte, P.C.; Traub, F.; Leithner, A.; Tunn, P.U.; Funovics, P.; Sys, G.; San-Julian, M.; Schaap, G.R.; Durr, H.R.; Hardes, J.; Healey, J.; Capanna, R.; Biau, D.; Gomez-Brouchet, A.; Wunder, J.; Cosker, T.D.A.; Laitinen, M.K.; Niu, X.; Kostiuk, V.; Sande, M.A.J. van de & Adamantinoma Res Grp (2020), Surgical outcome and oncological survival of osteofibrous dysplasia-like and classic adamantinomas an international multicenter study of 318 cases, Journal of Bone and Joint Surgery 102(19): 1703-1713.
- Palubeckaite, I.; Venneker, S.; Briaire-de Bruijn, I.H.; Akker, B.E. van den; Krol, A.D.; Gelderblom, H. & Bovee, J.V.M.G. (2020), Selection of effective therapies using three-dimensional in vitro modeling of chondrosarcoma, Frontiers in Molecular Biosciences 7.
- Martin, E.; Acem, I.; Grunhagen, D.J.; Bovee, J.V.M.G. & Verhoef, C. (2020), Prognostic significance of immunohistochemical markers and genetic alterations in malignant peripheral nerve sheath tumors: a systematic review, Frontiers in Oncology 10.
- Heijs, B.; Holst-Bernal, S.; Graaff, M.A. de; Briaire-de Bruijn, I.H.; Rodriguez-Girondo, M.; Sande, M.A.J. van de; Wuhrer, M.; McDonnell, L.A. & Bovee, J.V.M.G. (2020), Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging, Laboratory Investigation 100(9): 1252-1261.
- Saba, K.H.; Cornmark, L.; Hofvander, J.; Magnusson, L.; Nilsson, J.; Bos, H. van den; Spierings, D.C.J.; Foijer, F.; Staaf, J.; Brosjo, O.; Sumathi, V.P.; Lam, S.W.; Szuhai, K.; Bovee, J.V.M.G.; Kovac, M.; Baumhoer, D.; Styring, E. & Nord, K.H. (2020), Loss of NF2 defines a genetic subgroup of non-FOS-rearranged osteoblastoma, Journal of Pathology: Clinical Research 6(4): 231-237.
- Bosch, M.H.J. van den; Ramos, Y.F.M.; Hollander, W. den; Bomer, N.; Nelissen, R.G.H.H.; Bovee, J.V.M.G.; Berg, W.B. van den; Lent, P.L.E.M. van; Blom, A.B.; Kraan, P.M. van der & Meulenbelt, I. (2019), Increased WISP1 expression in human osteoarthritic articular cartilage is epigenetically regulated and decreases cartilage matrix production, Rheumatology 58(6): 1065-1074.
- Venneker, S.; Kruisselbrink, A.B.; Briaire-de Bruijn, I.H.; Jong, Y. de; Wijnen, A.J. van; Danen, E.H.J. & Bovee, J.V.M.G. (2019), Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status, Cancers 11(12).
- IJzendoorn, D.G.P. van; Szuhai, K.; Briaire-de Bruijn, I.H.; Kostine, M.; Kuijjer, M.L. & Bovee, J.V.M.G. (2019), Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas, PLoS Computational Biology 15(2).
- Lam, S.W.; IJzendoorn, D.G.P. van; Cleton-Jansen, A.M.; Szuhai, K. & Bovee, J.V.M.G. (2019), Molecular Pathology of Bone Tumors, Journal of Molecular Diagnostics 21(2): 171-182.
- Venneker, S.; Szuhai, K.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2019), Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma, Virchows Archiv.
- Bonvalot, S.; Rutkowski, P.L.; Thariat, J.; Carrere, S.; Ducassou, A.; Sunyach, M.P.; Agoston, P.; Hong, A.; Mervoyer, A.; Rastrelli, M.; Moreno, V.; Li, R.K.; Tiangco, B.; Herraez, A.C.; Gronchi, A.; Mangel, L.; Sy-Ortin, T.; Hohenberger, P.; Baere, T. de; Cesne, A. le; Helfre, S.; Saada-Bouzid, E.; Borkowska, A.; Anghel, R.; Co, A.; Gebhart, M.; Kantor, G.; Montero, A.; Loong, H.H.; Verges, R.; Lapeire, L.; Dema, S.; Kacso, G.; Austen, L.; Moureau-Zabotto, L.; Servois, V.; Wardelmann, E.; Terrier, P.; Lazar, A.J.; Bovee, J.V.M.G.; Pechoux, C. le & Papi, Z. (2019), NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): a multicentre, phase 2-3, randomised, controlled trial, Lancet Oncology 20(8): 1148-1159.
- Bovee, J.V.M.G. & Hogendoorn, P.C.W. (2019), Non-ossifying fibroma: A RAS-MAPK driven benign bone neoplasm, Journal of Pathology 248(2): 127-130.
- Maldegem, A. van; Conley, A.P.; Rutkowski, P.; Patel, S.R.; Lugowska, I.; Desar, I.M.E.; Bovee, J.V.M.G. & Gelderblom, H. (2019), Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma, Oncologist 24(1): 110-116.
- Majoor, B.C.J.; Sande, M.A.J. van de; Appelman-Dijkstra, N.M.; Leithner, A.; Jutte, P.C.; Velez, R.; Perlaky, T.; Staals, E.L.; Bovee, J.V.M.G.; Hamdy, N.A.T. & Dijkstra, S.P.D. (2019), Prevalence and Clinical Features of Mazabraud Syndrome A Multicenter European Study, Journal of Bone and Joint Surgery 101(2): 160-168.
- Jong, Y. de; Ingola, M.; Briaire-de Bruijn, I.H.; Kruisselbrink, A.B.; Venneker, S.; Palubeckaite, I.; Heijs, B.P.A.M.; Cleton-Jansen, A.M.; Haas, R.L.M. & Bovee, J.V.M.G. (2019), Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes, Clinical Sarcoma Research 9.
- Verschoor, A.J.; Speetjens, F.M.; Dijkstra, P.D.S.; Fiocco, M.; Sande, M.A.J. van de; Bovee, J.V.M.G. & Gelderblom, H. (2019), Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma, Oncologist.
- Song, W.Z.; Suurmeijer, A.J.H.; Bollen, S.M.; Cleton-Jansen, A.M.; Bovee, J.V.M.G. & Kroon, H.M. (2019), Soft tissue aneurysmal bone cyst: six new cases with imaging details, molecular pathology, and review of the literature, Skeletal Radiology 48(7): 1059-1067.
- Lam SW, Cleven A, Briaire-de Bruijn IIH & Bovee J (2019), Utility of FOS and FOSB Immunohistochemistry in Osteoid Osteoma and Osteoblastoma, Laboratory Investigation 99.
- Franceschini, N.; Lam, S.W.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2019), What's new in bone forming tumours of the skeleton?, Virchows Archiv.
- Lam SW, van Langevelde K, Suurmeijer AJH, Cleven AHG & Bov?e JVMG (2019), Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis, Histopathology 75(6): 843-852.
- Jong, Y. de; Bennani, F.; Oosterwijk, J.G. van; Alberti, G.; Baranski, Z.; Wijers-Koster, P.; Venneker, S.; Briaire-de Bruijn, I.H.; Akker, B.E. van de; Baelde, H.; Cleton-Jansen, A.M.; Water, B. van de; Danen, E.H.J. & Bovee, J.V.M.G. (2019), A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival, Journal of Bone Oncology 19.
- Lam SW, van Langevelde K, Suurmeijer AJH, Cleven AHG & Bov?e JVMG (2019), Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis, Histopathology 75(6): 843-852.
- Mastboom, M.J.L.; Hoek, D.M.; Bovee, J.V.M.G.; Sande, M.A.J. van de & Szuhai, K. (2019), Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?, Histopathology 74(2): 332-340.
- Addie, R.D.; Yvonne, D.; Alberti, G.; Kruisselbrink, A.B.; Que, I.; Baelde, H. & Bovee, J.V.M.G. (2019), Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway, Journal of Bone Oncology 15.
- Verschoor, A.J.; Bovee, J.V.M.G.; Mastboom, M.J.L.; Dijkstra, P.D.S.; Sande, M.A.J. van de & Gelderblom, H. (2018), Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study, Acta Orthopaedica 89(5): 570-574.
- Schaefer, I.M.; Hornick, J.L. & Bovee, J.V.M.G. (2018), The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms, Laboratory Investigation 98(4): 414-426.
- Verschoor, A.J.; Bovee, J.V.M.G.; Overbeek, L.I.H.; Hogendoorn, P.C.W.; Gelderblom, H. & PALGA Grp (2018), The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study, Virchows Archiv 472(2): 221-229.
- IJzendoorn, D.G.P. van; Sleijfer, S.; Gelderblom, H.; Eskens, F.A.L.M.; Leenders, G.J.L.H. van; Szuhai, K. & Bovee, J.V.M.G. (2018), Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma, Clinical Cancer Research 24(11): 2678-2687.
- Song, W.Z.; Berg, E. van den; Kwee, T.C.; Jutte, P.C.; Cleton-Jansen, A.M.; Bovee, J.V.M.G. & Suurmeijer, A.J. (2018), Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis, Clinical Sarcoma Research 8.
- Sande, M.A.J. van de; Bovee, J.V.M.G.; Domselaar, M. van; Wijk, M.J. van; Sanders, I. & Kuijper, E. (2018), Successful disinfection of femoral head bone graft using high hydrostatic pressure, Cell and Tissue Banking 19(3): 333-340.
- Peterse, E.F.P.; Niessen, B.; Addie, R.D.; Jong, Y. de; Cleven, A.H.G.; Kruisselbrink, A.B.; Akker, B.E.W.M. van den; Molenaar, R.J.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2018), Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation, British Journal of Cancer 118(8): 1074-1083.
- Lam, S.W.; Cleton-Jansen, A.M.; Cleven, A.H.G.; Ruano, D.; Wezel, T. van; Szuhai, K. & Bovee, J.V.M.G. (2018), Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing, Journal of Molecular Diagnostics 20(5): 653-663.
- Luk, S.J.; Steen, D.M. van der; Hagedoorn, R.S.; Jordanova, E.S.; Schilham, M.W.; Bovee, J.V.M.G.; Cleven, A.H.G.; Falkenburg, J.H.F.; Szuhai, K. & Heemskerk, M.H.M. (2018), PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy, OncoImmunology 7(12).
- Casali, P.G.; Abecassis, N.; Bauer, S.; Biagini, R.; Bielack, S.; Bonvalot, S.; Boukovinas, I.; Bovee, J.V.M.G.; Brodowicz, T.; Broto, J.M.; Buonadonna, A.; Alava, E.; Tos, A.P.; Muro, X.G.; Dileo, P.; Eriksson, M.; Fedenko, A.; Ferraresi, V.; Ferrari, A.; Ferrari, S.; Frezza, A.M.; Gasperoni, S.; Gelderblom, H.; Gil, T.; Grignani, G.; Gronchi, A.; Haas, R.L.; Hannu, A.; Hassan, B.; Hohenberger, P.; Issels, R.; Joensuu, H.; Jones, R.L.; Judson, I.; Jutte, P.; Kaal, S.; Kasper, B.; Kopeckova, K.; Krakorova, D.A.; Cesne, A.; Lugowska, I.; Merimsky, O.; Montemurro, M.; Pantaleo, M.A.; Piana, R.; Picci, P.; Piperno-Neumann, S.; Pousa, A.L.; Reichardt, P.; Robinson, M.H.; Rutkowski, P.; Safwat, A.A.; Schoffski, P.; Sleijfer, S.; Stacchiotti, S.; Hall, K.S.; Unk, M.; Coevorden, F.; Graaf, W.D.; Whelan, J.; Wardelmann, E.; Zaikova, O.; Blay, J.Y. & ESMO Guidelines Comm EURACAN (2018), Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology 29: 68-78.
- Jong, Y. de; Monderer, D.; Brandinelli, E.; Monchanin, M.; Akker, B.E. van den; Oosterwijk, J.G. van; Blay, J.Y.; Dutour, A. & Bovee, J.V.M.G. (2018), Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma, Oncogenesis 7.
- Casali, P.G.; Abecassis, N.; Aro, H.T.; Bauer, S.; Biagini, R.; Bielack, S.; Bonvalot, S.; Boukovinas, I.; Bovee, J.V.M.G.; Brodovvicz, T.; Broto, J.M.; Buonadonna, A.; Alava, E. de; Tos, A.P.D.; Muro, X.G. del; Dileo, P.; Eriksson, M.; Fedenko, A.; Ferraresi, V.; Ferrari, A.; Ferrari, S.; Frezza, A.M.; Gasperoni, S.; Gelderblom, H.; Gil, T.; Grignani, G.; Gronchi, A.; Haas, R.L.; Hassan, B.; Hohenberger, P.; Lssels, R.; Joensuu, H.; Jones, R.L.; Judson, I.; Jutte, P.; Kaal, S.; Kasper, B.; Kopeckova, K.; Krakorova, D.A.; Cesne, A. le; Lugowska, I.; Merimsky, O.; Montemurro, M.; Pantaleo, M.A.; Piana, R.; Picci, P.; Piperno-Neumann, S.; Pousa, A.L.; Reichardt, P.; Robinson, M.H.; Rutkovvski, P.; Safwat, A.A.; Schoffski, P.; Sleijfer, S.; Stacchiotti, S.; Hall, K.S.; Unk, M.; Coevorden, F. van; Graaf, W.T.A. van der; Whelan, J.; Wardelmann, E.; Zaikova, O.; Blay, J.Y.; ESMO Guidelines Comm & EURACAN (2018), Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg 51, 2018), Annals of Oncology 29: 268-269.
- Casali, P.G.; Bielack, S.; Abecassis, N.; Aro, H.T.; Bauer, S.; Biagini, R.; Bonvalot, S.; Boukovinas, I.; Bovee, J.V.M.G.; Brennan, B.; Brodowicz, T.; Broto, J.M.; Brugieres, L.; Buonadonna, A.; Alava, E. de; Tos, A.P.D.; Muro, X.G. del; Dileo, P.; Dhooge, C.; Eriksson, M.; Fagioli, F.; Fedenko, A.; Ferraresi, V.; Ferrari, A.; Ferrari, S.; Frezza, A.M.; Gaspar, N.; Gasperoni, S.; Gelderblom, H.; Gil, T.; Grignani, G.; Gronchi, A.; Haas, R.L.; Hassan, B.; Hecker-Nolting, S.; Hohenberger, P.; Issels, R.; Joensuu, H.; Jones, R.L.; Judson, I.; Jutte, P.; Kaal, S.; Kager, L.; Kasper, B.; Kopeckova, K.; Krakorova, D.A.; Ladenstein, R.; Cesne, A. le; Lugowska, I.; Merimsky, O.; Montemurro, M.; Morland, B.; Pantaleo, M.A.; Piana, R.; Picci, P.; Piperno-Neumann, S.; Pousa, A.L.; Reichardt, P.; Robinson, M.H.; Rutkowski, P.; Safwat, A.A.; Schoffski, P.; Sleijfer, S.; Stacchiotti, S.; Strauss, S.J.; Hall, K.S.; Unk, M.; Coevorden, F. van; Graaf, W.T.A. van der; Whelan, J.; Wardelmann, E.; Zaikova, O.; Blay, J.Y. & ESMO Guidelines Comm PaedCan (2018), Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology 29: 79-95.
- Veenstra, R.; Kostine, M.; Cleton-Jansen, A.M.; Miranda, N.F.C.C. de & Bovee, J.V.M.G. (2018), Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers, Laboratory Investigation 98(1): 41-50.
- Cleven Arjen, Reinink Frank, Briaire-de Bruijn Inge I. H., Cleton-Jansen Anne-Marie & Bovee Judith (2018), Immunohistochemistry of H3F3A G34W and H3F3 K36M as a diagnostic tool for giant cell tumor of bone and chondroblastoma, Modern Pathology 31: 20-20.
- Verschoor, A.J.; Warmerdam, F.A.R.M.; Bosse, T.; Bovee, J.V.M.G. & Gelderblom, H. (2018), A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report, BMC Cancer 18.
- Kostine, M.; Briaire-de Bruijn, I.H.; Cleven, A.H.G.; Vervat, C.; Corver, W.E.; Schilham, M.W.; Beelen, E. van; , H. van boven; Haas, R.L.; Italiano, A.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2018), Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies, OncoImmunology 7(2).
- Majoor, B.C.J.; Boyce, A.M.; Bovee, J.V.M.G.; Smit, V.T.H.B.M.; Collins, M.T.; Cleton-Jansen, A.M.; Dekkers, O.M.; Hamdy, N.A.T.; Dijkstra, P.D.S. & Appelman-Dijkstra, N.M. (2018), Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia, Journal of Bone and Mineral Research 33(1): 84-90.
- Martins-Neves, S.R.; Paiva-Oliveira, D.I.; Fontes-Ribeiro, C.; Bovee, J.V.M.G.; Cleton-Jansen, A.M. & Gomes, C.M.F. (2018), IWR-1, a tankyrase inhibitor, attenuates Wnt/beta-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft, Cancer Letters 414: 1-15.
- IJzendoorn, D.G. van; Hil, F. van den; Szuhai, K.; Bovee, J.V. & Orlova, V.V. (2018), Modeling translocation driven tumors with human induced pluripotent stem cells (hiPSCs) using CRISPR-Cas9: Pseudomyogenic hemangioendothelioma as a proof of principle, Cancer Research 78(13).
- Bosch, M.H. van den; Ramos, Y.F.; Hollander, W. den; Bomer, N.; Nelissen, R.G.; Bovee, J.V.; Blom, A.B. & Meulenbelt, I. (2017), INCREASED EXPRESSION OF CCN4/WISP1 IN OSTEOARTHRITIC ARTICULAR CARTILAGE IS EPIGENETICALLY REGULATED AND DISRUPTS CARTILAGE HOMEOSTASIS, Osteoarthritis and Cartilage 25: S38-S38.
- Bosch, M.H. van den; Ramos, Y.F.; Hollander, W. den; Bomer, N.; Nelissen, R.G.; Bovee, J.V.M.G.; Blom, A.B. & Meulenbelt, I. (2017), INCREASED EXPRESSION OF CCN4/WISP1 IN OSTEOARTHRITIC ARTICULAR CARTILAGE IS EPIGENETICALLY REGULATED AND DISRUPTS CARTILAGE HOMEOSTASIS, Annals of the Rheumatic Diseases 76: A69-A70.
- Bosch, M. van den; Ramos, Y.F.; Hollander, W. den; Bomer, N.; Nelissen, R.G.; Bovee, J.B.; Blom, A.B. & Meulenbelt, I. (2017), INCREASED EXPRESSION OF CCN4/ WISP1 IN OSTEOARTHRITIC ARTICULAR CARTILAGE IS EPIGENETICALLY REGULATED AND DISRUPTS CARTILAGE HOMEOSTASIS, Annals of the Rheumatic Diseases 76: 207-207.
- Groot, S. de; Gelderblom, H.; Fiocco, M.; Bovee, J.V.M.G.; Hoeven, J.J.M. van der; Pijl, H. & Kroep, J.R. (2017), Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy, OncoTargets and Therapy 10: 2963-2970.
- Bosch, M.H. van den; Ramos, Y.F.; Hollander, W. den; Bomer, N.; Nelissen, R.G.; Bovee, J.V.; Lent, P.L. van; Blom, A.B.; Kraan, P.M. van der & Meulenbelt, I. (2017), Increased Expression of CCN4/WISP1 in Osteoarthritic Articular Cartilage Is Epigenetically Regulated and Disrupts Cartilage Homeostasis, Arthritis and Rheumatology 69.
- Bekers, E.M.; Groenen, P.J.T.A.; Verdijk, M.A.J.; Raaijmakers-van Geloof, W.L.; Roepman, P.; Vink, R.; Gilhuijs, N.D.B.; Gorp, J.M. van; Bovee, J.V.M.G.; Creytens, D.H.; Flanagan, A.M.; Suurmeijer, A.J.H.; Mentzel, T.; Arbajian, E. & Flucke, U. (2017), Soft tissue angiofibroma: Clinicopathologic, immunohistochemical and molecular analysis of 14 cases, Genes, Chromosomes and Cancer 56(10): 750-757.
- Boon, E.; Graaf, W.T.A. van der; Gelderblom, H.; Tesselaar, M.E.T.; Es, R.J.J. van; Oosting, S.F.; Bree, R. de; Meerten, E. van; Hoeben, A.; Smeele, L.E.; Willems, S.M.; Witjes, M.J.H.; Buter, J.; Jong, R.J.B. de; Flucke, U.E.; Peer, P.G.M.; Bovee, J.V.M.G. & Herpen, C.M.L. van (2017), Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults, Head and Neck 39(1): 140-146.
- Ratcliffe, P.; Koivunen, P.; Myllyharju, J.; Ragoussis, J.; Bovee, J.V.; Batinic-Haberle, I.; Vinatier, C.; Trichet, V.; Robriquet, F.; Oliver, L. & Gardie, B. (2017), Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics, Hypoxia 5: 11-20.
- Cleven, A.H.G.; Suijker, J.; Agrogiannis, G.; Briaire-de Bruijn, I.H.; Frizzell, N.; Hoekstra, A.S.; Wijers-Koster, P.M.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2017), IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas, Clinical Sarcoma Research 7.
- Riester, S.M.; Torres-Mora, J.; Dudakovic, A.; Camilleri, E.T.; Wang, W.; Xu, F.H.; Thaler, R.R.; Evans, J.M.; Zwartbol, R.; Briaire-de Bruijn, I.H.; Maran, A.; Folpe, A.L.; Inwards, C.Y.; Rose, P.S.; Shives, T.C.; Yaszemski, M.J.; Sim, F.H.; Deyle, D.R.; Larson, A.N.; Galindo, M.A.; Cleven, A.G.H.; Oliveira, A.M.; Cleton-Jansen, A.M.; Bovee, J.V.M.G. & Wijnen, A.J. van (2017), Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma, Journal of Orthopaedic Research 35(5): 1137-1146.
- Graaff, M.A. de; Malu, S.; Guardiola, I.; Kruisselbrink, A.B.; Jong, Y. de; Corver, W.E.; Gelderblom, H.; Hwu, P.; Nielsen, T.O.; Lazar, A.J.; Somaiah, N. & Bovee, J.V.M.G. (2017), High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth, Translational Oncology 10(4): 546-554.
- Verboom, M.C.; Kloth, J.S.L.; Swen, J.J.; Straaten, T. van der; Bovee, J.V.M.G.; Sleijfer, S.; Reyners, A.K.L.; Mathijssen, R.H.J.; Guchelaar, H.J.; Steeghs, N. & Gelderblom, H. (2017), Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib, European Journal of Cancer 86: 226-232.
- IJzendoorn, D.G.P. van; Forghany, Z.; Liebelt, F.; Vertegaal, A.C.; Jochemsen, A.G.; Bovee, J.V.M.G.; Szuhai, K. & Baker, D.A. (2017), Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis, Journal of Biological Chemistry 292(52): 21282-21290.
- Sundara, Y.T.; Kostine, M.; Cleven, A.H.G.; Bovee, J.V.M.G.; Schilham, M.W. & Cleton-Jansen, A.M. (2017), Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy, Cancer Immunology, Immunotherapy 66(1): 119-128.
- Patel, N.R.; Chrisinger, J.S.A.; Demicco, E.G.; Sarabia, S.F.; Reuther, J.; Kumar, E.; Oliveira, A.M.; Billings, S.D.; Bovee, J.V.M.G.; Roy, A.; Lazar, A.J.; Lopez-Terrada, D.H. & Wang, W.L. (2017), USP6 activation in nodular fasciitis by promoter-swapping gene fusions, Modern Pathology 30(11): 1577-1588.
- Molenaar, R.J.; Coelen, R.J.S.; Khurshed, M.; Roos, E.; Caan, M.W.A.; Linde, M.E. van; Kouwenhoven, M.; Bramer, J.A.M.; Bovee, J.V.M.G.; Mathot, R.A.; Klumpen, H.J.; Laarhoven, H.W.M. van; Noorden, C.J.F. van; Vandertop, W.P.; Gelderblom, H.; Gulik, T.M. van & Wilmink, J.W. (2017), Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours, BMJ Open 7(6).
- Hoekstra, A.S.; Hensen, E.F.; Jordanova, E.S.; Korpershoek, E.; Horst-Schrivers, A.N.A. van der; Cornelisse, C.; Corssmit, E.P.M.; Hes, F.J.; Jansen, J.C.; Kunst, H.P.M.; Timmers, H.J.L.M.; Bateman, A.; Eccles, D.; Bovee, J.V.M.G.; Devilee, P. & Bayley, J.P. (2017), Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas, Oncotarget 8(9): 14525-14536.
- Peterse, E.F.P.; Akker, B.E.W.M. van den; Niessen, B.; Oosting, J.; Suijker, J.; Jong, Y. de; Danen, E.H.J.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2017), NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma, Molecular Cancer Research 15(12): 1714-1721.
- Mastboom, M.J.L.; Verspoor, F.G.M.; Verschoor, A.J.; Uittenbogaard, D.; Nemeth, B.; Mastboom, W.J.B.; Bovee, J.V.M.G.; Dijkstra, P.D.S.; Schreuder, H.W.B.; Gelderblom, H.; Sande, M.A.J. van de & TGCT Study Grp (2017), Higher incidence rates than previously known in tenosynovial giant cell tumors A nationwide study in The Netherlands, Acta Orthopaedica 88(6): 688-694.
- Lou, S.; Balluff, B.; Cleven, A.H.G.; Bovee, J.V.M.G. & McDonnell, L.A. (2017), Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging, Journal of The American Society for Mass Spectrometry 28(2): 376-383.
- Lou, S.; Balluff, B.; Cleven, A.H.G.; Bovee, J.V.M.G. & McDonnell, L.A. (2017), An experimental guideline for the analysis of histologically heterogeneous tumors by MALDI-TOF mass spectrometry imaging, BBA - Proteins and Proteomics 1865(7): 957-966.
- Jong Y. de, Oosterwijk J.G. van, Kruisselbrink A.B., Briaire I.H., Agrogiannis G., Baranski Madrigal Z., Cleven A.H., Cleton A.M., Water B. van de, Danen E.H.J. & Bovée J.V.M.G. (2016), Targeting survivin as a potential new treatment for chondrosarcoma of bone, Oncogenesis 5: e222.
- Peterse E.F.P., Cleven A.H.G., Jong Y. de, Briaire-de Bruijn I., Fletcher J.A., Danen E.H.J., Cleton A.M. & Bov'ee J.V.M.G. (2016), No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone, BMC Cancer 16: 475.
- Hoekstra, A.S.; Addie, R.D.; Ras, C.; Seifar, R.M.; Ruivenkamp, C.A.; Briaire-de Bruijn, I.H.; Hes, F.J.; Jansen, J.C.; Corssmit, E.P.M.; Corver, W.E.; Morreau, H.; Bovee, J.V.M.G.; Bayley, J.P. & Devilee, P. (2016), Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers, Human Molecular Genetics 25(17): 3715-3728.
- Lou, S.; Balluff, B.; Graaff, M.A. de; Cleven, A.H.G.; Briaire-de Bruijn, I.; Bovee, J.V.M.G. & McDonnell, L.A. (2016), High-grade sarcoma diagnosis and prognosis: Biomarker discovery by mass spectrometry imaging, Proteomics 16(11-12): 1802-1813.
- Heijs, B.; Holst, S.; Briaire-de Bruijn, I.H.; Pelt, G.W. van; Ru, A.H. de; Veelen, P.A. van; Drake, R.R.; Mehta, A.S.; Mesker, W.E.; Tollenaar, R.A.; Bovee, J.V.M.G.; Wuhrer, M. & McDonnell, L.A. (2016), Multimodal Mass Spectrometry Imaging of N-Glycans and Proteins from the Same Tissue Section, Analytical Chemistry 88(15): 7745-7753.
- Holst, S.; Heijs, B.; Haan, N. de; Zeijl, R.J.M. van; Briaire-de Bruijn, I.H.; Pelt, G.W. van; Mehta, A.S.; Angel, P.M.; Mesker, W.E.; Tollenaar, R.A.; Drake, R.R.; Bovee, J.V.M.G.; McDonnell, L.A. & Wuhrer, M. (2016), Linkage-Specific in Situ Sialic Acid Derivatization for N-Glycan Mass Spectrometry Imaging of Formalin-Fixed Paraffin-Embedded Tissues, Analytical Chemistry 88(11): 5904-5913.
- Lou, S.; Cleven, A.H.G.; Balluff, B.; Graaff, M. de; Kostine, M.; Briaire-de Bruijn, I.; McDonnell, L.A. & Bovee, J.V.M.G. (2016), High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas, Clinical Sarcoma Research 6.
- Kostine, M.; Cleven, A.H.G.; Miranda, N.F.C.C. de; Italiano, A.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2016), Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype, Modern Pathology 29(9): 1028-1037.
- Martins-Neves, S.R.; Paiva-Oliveira, D.I.; Wijers-Koster, P.M.; Abrunhosa, A.J.; Fontes-Ribeiro, C.; Bovee, J.V.M.G.; Cleton-Jansen, A.M. & Gomes, C.M.F. (2016), Chemotherapy induces sternness in osteosarcoma cells through activation of Wnt/beta-catenin signaling, Cancer Letters 370(2): 286-295.
- Peterse, E.F.P. & Bovee, J.V.M.G. (2016), CORR Insights (R): Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-beta as Involved in the Pathogenesis of Osteosarcoma, Clinical Orthopaedics and Related Research 474(1): 190-192.
- Kumar, E.; Patel, N.R.; Demicco, E.G.; Bovee, J.V.M.G.; Olivera, A.M.; Lopez-Terrada, D.H.; Billings, S.D.; Lazar, A.J. & Wang, W.L. (2016), Cutaneous nodular fasciitis with genetic analysis: a case series, Journal of Cutaneous Pathology 43(12): 1143-1149.
- Cleven, A.H.G.; Briaire-de Bruijn, I.; Szuhai, K. & Bovee, J.V.M.G. (2016), DOG1 expression in giant-cell-containing bone tumours, Histopathology 68(6): 942-945.
- Graaff, M.A. de; Yu, J.S.E.; Beird, H.C.; Ingram, D.R.; Nguyen, T.; Liu, J.J.; Bolshakov, S.; Szuhai, K.; Aman, P.; Torres, K.E.; Lev, D.; Nielsen, T.O.; Bovee, J.V.M.G.; Lazar, A.J. & Somaiah, N. (2016), Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation, Laboratory Investigation 96(8): 885-894.
- Wardelmann, E.; Haas, R.L.; Bovee, J.V.M.G.; Terrier, P.; Lazar, A.; Messiou, C.; LePechoux, C.; Hartmann, W.; Collin, F.; Fisher, C.; Mechtersheimer, G.; DeiTos, A.P.; Stacchiotti, S.; Jones, R.L.; Gronchi, A. & Bonvalot, S. (2016), Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting, European Journal of Cancer 53: 84-95.
- Messiou, C.; Bonvalot, S.; Gronchi, A.; Vanel, D.; Meyer, M.; Robinson, P.; Morosi, C.; Bloem, J.L.; Terrier, P.H.; Lazar, A.; Pechoux, C. le; Wardelman, E.; Winfield, J.M.; Boulet, B.; Bovee, J. & Haas, R.L. (2016), Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC - STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging, European Journal of Cancer 56: 37-44.
- Maldegem, A.M. van; Bovee, J.V.M.G.; Peterse, E.F.P.; Hogendoorn, P.C.W. & Gelderblom, H. (2016), Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway, European Journal of Cancer 53: 171-180.
- Graaff, M.A. de; Rooij, M.A.J. de; Akker, B.E.W.M. van den; Gelderblom, H.; Chibon, F.; Coindre, J.M.; Marino-Enriquez, A.; Fletcher, J.A.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2016), Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy, British Journal of Cancer 114(11): 1219-1226.
- Jong, Y. de; Maldegem, A.M. van; Marino-Enriquez, A.; Jong, D. de; Suijker, J.; Briaire-de Bruijn, I.H.; Kruisselbrink, A.B.; Cleton-Jansen, A.M.; Szuhai, K.; Gelderblom, H.; Fletcher, J.A. & Bovee, J.V.M.G. (2016), Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line, Laboratory Investigation 96(10): 1128-1137.
- Cleven, A.H.G.; Sannaa, G.A. al; Briaire-de Bruijn, I.; Ingram, D.R.; Rijn, M. van de; Rubin, B.P.; Vries, M.W. de; Watson, K.L.; Torres, K.E.; Wang, W.L.; Duinen, S.G. van; Hogendoorn, P.C.W.; Lazar, A.J. & Bovee, J.V.M.G. (2016), Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival, Modern Pathology 29(6): 582-590.
- Speetjens, F.M.; Jong, Y. de; Gelderblom, H. & Bovee, J.V.M.G. (2016), Molecular oncogenesis of chondrosarcoma: impact for targeted treatment, Current Opinion in Oncology 28(4): 314-322.
- Peterse, E.F.P.; Cleven, A.H.G.; Jong, Y. de; Briaire-de Bruijn, I.; Fletcher, J.A.; Danen, E.H.J.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2016), No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone, BMC Cancer 16.
- Martins-Neves, S.R.; Corver, W.E.; Paiva-Oliveira, D.I.; Akker, B.E.W.M. van den; Briaire-De-Bruijn, I.H.; Bovee, J.V.M.G.; Gomes, C.M.F. & Cleton-Jansen, A.M. (2016), Osteosarcoma Stem Cells Have Active Wnt/beta-catenin and Overexpress SOX2 and KLF4, Journal of Cellular Physiology 231(4): 876-886.
- Maldegem, A.M. van; Bovee, J.V.M.G. & Gelderblom, H. (2016), PanobinostatA Potential Treatment for Metastasized Ewing Sarcoma? A Case Report, Pediatric Blood and Cancer 63(10): 1840-1843.
- Jong, Y. de; Oosterwijk, J.G. van; Kruisselbrink, A.B.; Briaire-de Bruijn, I.H.; Agrogiannis, G.; Baranski, Z.; Cleven, A.H.G.; Cleton-Jansen, A.M.; Water, B. van de; Danen, E.H.J. & Bovee, J.V.M.G. (2016), Targeting survivin as a potential new treatment for chondrosarcoma of bone, Oncogenesis 5.
- Tieken, C.; Verboom, M.C.; Ruf, W.; Gelderblom, H.; Bovee, J.V.M.G.; Reitsma, P.H.; Cleton-Jansen, A.M. & Versteeg, H.H. (2016), Tissue factor associates with survival and regulates tumour progression in osteosarcoma, Thrombosis and Haemostasis 115(5): 1025-1033.
- Hoekstra, A.S.; Graaff, M.A. de; Briaire-de Bruijn, I.H.; Ras, C.; Seifar, R.M.; Minderhout, I. van; Cornelisse, C.J.; Hogendoorn, P.C.W.; Breuning, M.H.; Suijker, J.; Korpershoek, E.; Kunst, H.P.M.; Frizzell, N.; Devilee, P.; Bayley, J.P. & Bovee, J.V.M.G. (2015), Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors, Oncotarget 6(36): 38777-38788.
- Willeumier, J.; Fiocco, M.; Nout, R.; Dijkstra, S.; Aston, W.; Pollock, R.; Hartgrink, H.; Bovee, J. & Sande, M. van de (2015), High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survival, International Orthopaedics 39(5): 935-941.
- IJzendoorn, D.G.P. van; Jong, D. de; Romagosa, C.; Picci, P.; Benassi, M.S.; Gambarotti, M.; Daugaard, S.; Sande, M. van de; Szuhai, K. & Bovee, J.V.M.G. (2015), Fusion events lead to truncation of FOS in epithelioid hemangioma of bone, Genes, Chromosomes and Cancer 54(9): 565-574.
- Andrea, C.E. de; Zhu, J.F.; Jin, H.F.; Bovee, J.V.M.G. & Jones, K.B. (2015), Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency, Journal of Pathology 236(2): 210-218.
- Baranski, Z.; Booij, T.H.; Cleton-Jansen, A.M.; Price, L.S.; Water, B. van de; Bovee, J.V.M.G.; Hogendoorn, P.C.W. & Danen, E.H.J. (2015), Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma, Journal of Pathology 236(3): 348-359.
- Oosterwijk, J.G. van; Plass, J.R.M.; Meijer, D.; Que, I.; Karperien, M. & Bovee, J.V.M.G. (2015), An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing, Virchows Archiv 466(1): 101-109.
- Graaff, M.A. de; Jong, D. de; Briaire-De Bruijn, I.H.; Hogendoorn, P.C.W.; Bovee, J.V.M.G. & Szuhai, K. (2015), A translocation t(6;14) in two cases of leiomyosarcoma: Molecular cytogenetic and array-based comparative genomic hybridization characterization, Cancer Genetics 208(11): 537-544.
- Suijker, J.; Oosting, J.; Koornneef, A.; Struys, E.A.; Salomons, G.S.; Schaap, F.G.; Waaijer, C.J.F.; Wijers-Koster, P.M.; Bruijn, I.H.B.D.; Haazen, L.; Riester, S.M.; Dudakovic, A.; Danen, E.; Cleton-Jansen, A.M.; Wijnen, A.J. van & Bovee, J.V.M.G. (2015), Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines, Oncotarget 6(14): 12505-12519.
- Heijs, B.; Tolner, E.A.; Bovee, J.V.M.G.; Maagdenberg, A.M.J.M. van den & McDonnell, L.A. (2015), Brain Region-Specific Dynamics of On-Tissue Protein Digestion Using MALDI Mass Spectrometry Imaging, Journal of Proteome Research 14(12): 5348-5354.
- Addie, R.D.; Balluff, B.; Bovee, J.V.M.G.; Morreau, H. & McDonnell, L.A. (2015), Current State and Future Challenges of Mass Spectrometry Imaging for Clinical Research, Analytical Chemistry 87(13): 6426-6433.
- Verbeke, S.L.J.; Jong, D. de; Bertoni, F.; Sciot, R.; Antonescu, C.R.; Szuhai, K. & Bovee, J.V.M.G. (2015), Array CGH Analysis Identifies Two Distinct Subgroups of Primary Angiosarcoma of Bone, Genes, Chromosomes and Cancer 54(2): 72-81.
- Suijker, J.; Baelde, H.J.; Roelofs, H.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2015), The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or-2 blocks osteoblast differentiation in vitro and in vivo, Oncotarget 6(17): 14832-14842.
- Verschoor, A.J.; Cleton-Jansen, A.M.; Wijers-Koster, P.; Coffin, C.M.; Lazar, A.J.; Nout, R.A.; Rubin, B.P.; Gelderblom, H. & Bovee, J.V.M.G. (2015), Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor, American Journal of Surgical Pathology 39(12): 1701-1707.
- Halteren, A. van; Blijleven, L.; Steenwijk, E.; Unen, V. van; Quispel, W.; Eijk, R. van; Bovee, J.; Egeler, M.; Abla, O. & Bos, C. van den (2015), LCH REACTIVATION RISK IS AFFECTED BY LESIONAL CD8+T CELL PERCENTAGE BUT NOT BY BRAF MUTATIONAL STATUS, Pediatric Blood and Cancer 62: S139-S140.
- Heijs, B.; Abdelmoula, W.M.; Lou, S.; Briaire-de Bruijn, I.H.; Dijkstra, J.; Bovee, J.V.M.G. & McDonnell, L.A. (2015), Histology-Guided High-Resolution Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging, Analytical Chemistry 87(24): 11978-11983.
- Stomp, W.; Reijnierse, M.; Kloppenburg, M.; Mutsert, R. de; Bovee, J.V.M.G.; Heijer, M. den; Bloem, J.L. & NEO Study Grp (2015), Prevalence of cartilaginous tumours as an incidental finding on MRI of the knee, European Radiology 25(12): 3480-3487.
- Baranski, Z.; Jong, Y. de; Ilkova, T.; Peterse, E.F.P.; Cleton-Jansen, A.M.; Water, B. van de; Hogendoorn, P.C.W.; Bovee, J.V.M.G. & Danen, E.H.J. (2015), Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin, Oncotarget 6(34): 36113-36125.
- Cleven, A.H.G.; Zwartkruis, E.; Hogendoorn, P.C.W.; Kroon, H.M.; Briaire-de Bruijn, I. & Bovee, J.V.M.G. (2015), Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype, Histopathology 67(4): 483-490.
- Endo, M.; Graaff, M.A. de; Ingram, D.R.; Lim, S.; Lev, D.C.; Riaire-De Bruijn, I.H.; Somaiah, N.; Bovee, J.V.M.G.; Lazar, A.J. & Nielseni, T.O. (2015), NY-ESO-1 (CTAG1B) expression in mesenchymal tumors, Modern Pathology 28(4): 587-595.
- Cleven, A.H.G.; Hocker, S.; Briaire-de Bruijn, I.; Szuhai, K.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2015), Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma, American Journal of Surgical Pathology 39(11): 1576-1583.
- Bollen, L.; Wibmer, C.; Wang, M.; Linden, Y.M. van der; Leithner, A.; Bunger, C.E.; Jensen, A.B.; Fiocco, M.; Bratschitsch, G.; Pondaag, W.; Bovee, J.V.M.G. & Dijkstra, P.D.S. (2015), Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases, Clinical and Experimental Metastasis 32(1): 1-5.
- Nelson, D.S.; Halteren, A. van; Quispel, W.T.; Bos, C. van den; Bovee, J.V.M.G.; Patel, B.; Badalian-Very, G.; Hummelen, P. van; Ducar, M.; Lin, L.; MacConaill, L.E.; Egeler, R.M. & Rollins, B.J. (2015), MAP2K1 and MAP3K1 Mutations in Langerhans Cell Histiocytosis, Genes, Chromosomes and Cancer 54(6): 361-368.
- Luks, V.L.; Kamitaki, N.; Vivero, M.P.; Uller, W.; Rab, R.; Bovee, J.V.M.G.; Rialon, K.L.; Guevara, C.J.; Alomari, A.I.; Greene, A.K.; Fishman, S.J.; Kozakewich, H.P.W.; Maclellan, R.A.; Mulliken, J.B.; Rahbar, R.; Spencer, S.A.; Trenor, C.C.; Upton, J.; Zurakowski, D.; Perkins, J.A.; Kirsh, A.; Bennett, J.T.; Dobyns, W.B.; Kurek, K.C.; Warman, M.L.; McCarroll, S.A. & Murillo, R. (2015), Lymphatic and Other Vascular Malformative/Overgrowth Disorders Are Caused by Somatic Mutations in PIK3CA, Journal of Pediatrics 166(4): 1048-U376.
- Pahl, J.H.W.; Santos, S.J.; Kuijjer, M.L.; Boerman, G.H.; Sand, L.G.L.; Szuhai, K.; Cleton-Jansen, A.; Egeler, R.M.; Bovee, J.V.M.G.; Schilham, M.W. & Lankester, A.C. (2015), Expression of the immune regulation antigen CD70 in osteosarcoma, Cancer Cell International 15.
- Nord, K.H.; Lilljebjorn, H.; Vezzi, F.; Nilsson, J.; Magnusson, L.; Tayebwa, J.; Jong, D. de; Bovee, J.V.M.G.; Hogendoorn, P.C.W. & Szuhai, K. (2014), GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma, Nature Genetics 46(5): 474-477.
- Wiweger, M.I.; Andrea, C.E. de; Scheepstra, K.W.F.; Zhao, Z. & Hogendoorn, P.C.W. (2014), Possible effects of EXT2 on mesenchymal differentiation - lessons from the zebrafish, Orphanet Journal of Rare Diseases 9.
- Ramos, Y.F.M.; Hollander, W. den; Bovee, J.V.M.G.; Bomer, N.; Breggen, R. van der; Lakenberg, N.; Keurentjes, J.C.; Goeman, J.J.; Slagboom, P.E.; Nelissen, R.G.H.H.; Bos, S.D. & Meulenbelt, I. (2014), Genes Involved in the Osteoarthritis Process Identified through Genome Wide Expression Analysis in Articular Cartilage; the RAAK Study, PLoS ONE 9(7).
- Heijden, L. van der; Dijkstra, P.D.S.; Sande, M.A.J. van de; Kroep, J.R.; Nout, R.A.; Rijswijk, C.S.P. van; Bovee, J.V.M.G.; Hogendoorn, P.C.W. & Gelderblom, H. (2014), Giant Cell Tumor of Bone Reply, The Oncologist 19(11): 1208-1208.
- Engen-van Grunsven, A.C.H. van; Kusters-Vandevelde, H.V.N.; Hullu, J. de; Duijn, L.M. van; Rijntjes, J.; Bovee, J.V.M.G.; Groenen, P.J.T.A. & Blokx, W.A.M. (2014), NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract-A study of 24 cases from the Netherlands, Gynecologic Oncology 134(1): 10-14.
- Maldegem, A.M. van; Gelderblom, H.; Palmerini, E.; Dijkstra, S.D.; Gambarotti, M.; Ruggieri, P.; Nout, R.A.; Sande, M.A.J. van de; Ferrari, C.; Ferrari, S.; Bovee, J.V.M.G. & Picci, P. (2014), Outcome of Advanced, Unresectable Conventional Central Chondrosarcoma, Cancer 120(20): 3159-3164.
- Nelson, D.S.; Quispel, W.; Badalian-Very, G.; Halteren, A.G.S. van; Bos, C. van den; Bovee, J.V.M.G.; Tian, S.Y.; Hummelen, P. van; Ducar, M.; MacConaill, L.E.; Egeler, R.M. & Rollins, B.J. (2014), Somatic activating ARAF mutations in Langerhans cell histiocytosis, Blood 123(20): 3152-3155.
- Mohseny, A.B.; Hogendoorn, P.C.W. & Kleinerman, E.S. (2014), Zebrafish as a Model for Human Osteosarcoma, Advances in Experimental Medicine and Biology 804: 221-236.
- Szuhai, K.; Jong, D. de; Leung, W.Y.; Fletcher, C.D.M. & Hogendoorn, P.C.W. (2014), Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma, Journal of Pathology 232(3): 300-307.
- Heijden, L. van der; Dijkstra, P.D.S.; Sande, M.A.J. van de; Kroep, J.R.; Nout, R.A.; Rijswijk, C.S.P. van; Bovee, J.V.M.G.; Hogendoorn, P.C.W. & Gelderblom, H. (2014), The Clinical Approach Toward Giant Cell Tumor of Bone, The Oncologist 19(5): 550-561.
- Pappo, A.S.; Vassal, G.; Crowley, J.J.; Bolejack, V.; Hogendoorn, P.C.W.; Chugh, R.; Ladanyi, M.; Grippo, J.F.; Dall, G.; Staddon, A.P.; Chawla, S.P.; Maki, R.G.; Araujo, D.M.; Geoerger, B.; Ganjoo, K.; Marina, N.; Blay, J.Y.; Schuetze, S.M.; Chow, W.A. & Helman, L.J. (2014), A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study, Cancer 120(16): 2448-2456.
- Gelderblom, H.; Blay, J.Y.; Seddon, B.M.; Leahy, M.; Ray-Coquard, I.; Sleijfer, S.; Kerst, J.M.; Rutkowski, P.; Bauer, S.; Ouali, M.; Marreaud, S.; Straaten, R.J.H.M. van der; Guchelaar, H.J.; Weitman, S.D.; Hogendoorn, P.C.W. & Hohenberger, P. (2014), Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study, European Journal of Cancer 50(2): 388-396.
- Kajtar, B.; Tornoczky, T.; Kalman, E.; Kuzsner, J.; Hogendoorn, P.C.W. & Szuhai, K. (2014), CD99-positive undifferentiated round cell sarcoma diagnosed on fine needle aspiration cytology, later found to harbour a CIC-DUX4 translocation: a recently described entity, Cytopathology 25(2): 129-132.
- Beletkaia, E.; Fenz, S.; Snaar-Jagalska, E.; Hogendoorn, P. & Schmidt, T. (2014), The Molecular Mechanisms of Gradient Sensing by CXCR4, Biophysical Journal 106(2): 519A-519A.
- Rajnai, H.; Heyning, F.H.; Koens, L.; Sebestyen, A.; Andrikovics, H.; Hogendoorn, P.C.W.; Matolcsy, A. & Szepesi, A. (2014), The density of CD8+T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone, Virchows Archiv 464(2): 229-239.
- Buhnemann, C.; Li, S.; Yu, H.Y.; White, H.B.; Schafer, K.L.; Llombart-Bosch, A.; Machado, I.; Picci, P.; Hogendoorn, P.C.W.; Athanasou, N.A.; Noble, J.A. & Hassan, A.B. (2014), Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis, PLoS ONE 9(9).
- Kuijjer, M.L.; Akker, B.E.W.M. van den; Hilhorst, R.; Mommersteeg, M.; Buddingh, E.P.; Serra, M.; Burger, H.; Hogendoorn, P.C.W. & Cleton-Jansen, A.M. (2014), Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy, BMC Medical Genomics 7.
- Sand, L.; Szuhai, K.; Berghuis, D. & Hogendoorn, P.C.W. (2014), CXCR4 splice variant ratio, CXCL14 and CXCR7 predict survival in Ewing sarcoma by inhibiting CXCR4 activation, Virchows Archiv 465: S17-S17.
- Judson, I.; Verweij, J.; Gelderblom, H.; Hartmann, J.T.; Schoffski, P.; Blay, J.Y.; Kerst, J.M.; Sufliarsky, J.; Whelan, J.; Hohenberger, P.; Krarup-Hansen, A.; Alcindor, T.; Marreaud, S.; Litiere, S.; Hermans, C.; Fisher, C.; Hogendoorn, P.C.W.; Tos, A.P. dei; Graaf, W.T.A. van der; European Org & Treatment Canc Soft Tissue Bone Sa (2014), Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial, The Lancet Oncology 15(4): 415-423.
- Roukens, A.H.; Kroep, J.R.; Marinkovic, M.; Nout, R.A.; Bovee, J.V.M.G.; Vasylenko, Y.; Gelderblom, H. & Lutyen, G.P.M. (2014), Primary Ewing sarcoma of the iris, Lancet 383(9913): 256-256.
- Cesne, A. le; Ouali, M.; Leahy, M.G.; Santoro, A.; Hoekstra, H.J.; Hohenberger, P.; Coevorden, F. van; Rutkowski, P.; Hoesel, R. van; Verweij, J.; Bonvalot, S.; Steward, W.P.; Gronchi, A.; Hogendoorn, P.C.W.; Litiere, S.; Marreaud, S.; Blay, J.Y. & Graaf, W.T.A. van der (2014), Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials, Annals of Oncology 25(12): 2425-2432.
- Ent, W. van der; Jochemsen, A.G.; Teunisse, A.F.A.S.; Krens, S.F.G.; Szuhai, K.; Spaink, H.P.; Hogendoorn, P.C.W. & Snaar-Jagalska, B.E. (2014), Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53, Journal of Pathology 233(4): 415-424.
- Lieveld, M.; Bodson, E.; Boeck, G. de; Nouman, B.; Cleton-Jansen, A.M.; Korsching, E.; Benassi, M.S.; Picci, P.; Sys, G.; Poffyn, B.; Athanasou, N.A.; Hogendoorn, P.C.W. & Forsyth, R.G. (2014), Gene expression profiling of giant cell tumor of bone reveals downregulation of extracellular matrix components decorin and lumican associated with lung metastasis, Virchows Archiv 465(6): 703-713.
- Schaap, F.G.; French, P.J. & Bovee, J.V.M.G. (2013), Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors, Advances in Anatomic Pathology 20(1): 32-38.
- Kurek, K.C.; Pansuriya, T.C.; Ruler, M.A.J.H. van; Akker, B. van den; Luks, V.; Verbeke, S.L.J.; Kozakewich, H.P.; Sciot, R.; Lev, D.; Lazar, A.J.; Fletcher, C.D.M. & Bovee, J.V.M.G. (2013), R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations.
- Kurek, K.C.; Pansuriya, T.C.; Ruler, M.A.J.H. van; Akker, B. van den; Luks, V.; Verbeke, S.L.J.; Kozakewich, H.P.; Sciot, R.; Lev, D.; Lazar, A.J.; Fletcher, C.D.M. & Bovee, J.V.M.G. (2013), R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations.
- Waaijer, C.J.F.; Winter, M.G.T.; Reijnders, C.M.A.; Jong, D. de; Ham, S.J.; Bovee, J.V.M.G. & Szuhai, K. (2013), Intronic deletion and duplication proximal of the EXT1 gene: A novel causative mechanism for multiple osteochondromas, Genes, Chromosomes and Cancer 52(4): 431-436.
- Kurek, K.C.; Pansuriya, T.C.; Ruler, M.A.J.H. van; Akker, B. van den; Luks, V.L.; Verbeke, S.L.J.; Kozakewich, H.P.; Sciot, R.; Lev, D.; Lazar, A.J.; Fletcher, C.D.M. & Bovee, J.V.M.G. (2013), R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations, American Journal of Pathology 182(5): 1494-1500.
- Felderhof, J.M.; Creutzberg, C.L.; Putter, H.; Nout, R.A.; Bovee, J.V.M.G.; Dijkstra, P.D.S.; Hartgrink, H.H. & Marijnen, C.A.M. (2013), Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy, Acta Oncologica 52(4): 745-752.
- Bielack, S.S.; Smeland, S.; Whelan, J.; Marina, N.; Hook, J.; Jovic, G.; Krailo, M.D.; Butterfass-Bahloul, T.; Kuhne, T.; Eriksson, M.; Teot, L.A.; Gelderblom, H.; Kager, L.; Hall, K.S.; Gorlick, R.G.; Randall, R.L.; Hogendoorn, P.C.W.; Calaminus, G.; Sydes, M.R. & Bernstein, M.L. (2013), MAP plus maintenance pegylated interferon alpha-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization., Journal of Clinical Oncology 31(15).
- Nord, K.H.; Nilsson, J.; Arbajian, E.; Steyern, F.V. von; Brosjo, O.; Cleton-Jansen, A.M.; Szuhai, K. & Hogendoorn, P.C.W. (2013), Recurrent Chromosome 22 Deletions in Osteoblastoma Affect Inhibitors of the Wnt/Beta-Catenin Signaling Pathway, PLoS ONE 8(11).
- Kuijjer, M.L.; Hogendoorn, P.C.W. & Cleton-Jansen, A.M. (2013), Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor, International Journal of Cancer 133(11): 2512-2521.
- Verbeke, S.L.J.; Bertoni, F.; Bacchini, P.; Oosting, J.; Sciot, R.; Krenacs, T. & Bovee, J.V.M.G. (2013), Active TGF-beta signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart, Modern Pathology 26(9): 1211-1221.
- Colombo, C.; Miceli, R.; Lazar, A.J.; Perrone, F.; Pollock, R.E.; Cesne, A. le; Hartgrink, H.H.; Cleton-Jansen, A.M.; Domont, J.; Bovee, J.V.M.G.; Bonvalot, S.; Lev, D. & Gronchi, A. (2013), CTNNB1 45F Mutation Is a Molecular Prognosticator of Increased Postoperative Primary Desmoid Tumor Recurrence An Independent, Multicenter Validation Study, Cancer 119(20): 3696-3702.
- Zhang, Y.X.; Oosterwijk, J.G. van; Sicinska, E.; Moss, S.; Remillard, S.P.; Wezel, T. van; Uhnemann, C.B.; Hassan, A.B.; Demetri, G.D.; Bovee, J.V.M.G. & Wagner, A.J. (2013), Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy, Clinical Cancer Research 19(14): 3796-3807.
- Liebrechts-Akkerman, G.; Bovee, J.V.M.G.; Wijnaendts, L.C.D.; Maes, A.; Nikkels, P.G.J. & Krijger, R.R. de (2013), Histological Findings in Unclassified Sudden Infant Death, Including Sudden Infant Death Syndrome, Pediatric and Developmental Pathology 16(3): 168-176.
- Slieker, R.C.; Bos, S.D.; Goeman, J.J.; Bovee, J.V.M.G.; Talens, R.P.; Breggen, R. van der; Suchiman, H.E.D.; Lameijer, E.W.; Putter, H.; Akker, E.B. van den; Zhang, Y.J.; Jukema, J.W.; Slagboom, P.E.; Meulenbelt, I. & Heijmans, B.T. (2013), Identification and systematic annotation of tissue-specific differentially methylated regions using the Illumina 450k array, Epigenetics and Chromatin 6.
- Jones, E.A.; Schmitz, N.; Waaijer, C.J.F.; Frese, C.K.; Remoortere, A. van; Zeijl, R.J.M. van; Heck, A.J.R.; Hogendoorn, P.C.W.; Deelder, A.M.; Altelaar, A.F.M.; Bovee, J.V.M.G. & McDonnell, L.A. (2013), Imaging Mass Spectrometry-based Molecular Histology Differentiates Microscopically Identical and Heterogeneous Tumors, Journal of Proteome Research 12(4): 1847-1855.
- Bovee, J.V.M. (2013), In Vitro and In Vivo Models in the Study of Bone Sarcomas, Journal of Pathology 231: 11-11.
- Graaff, M.A. de; Cleton-Jansen, A.M.; Szuhai, K. & Bovee, J.V.M.G. (2013), Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity, Human Pathology 44(8): 1597-1604.
- Cleton-Jansen, A.M.; Wijers-Koster, P.M.; Coffin, C.M.; Rubin, B.P. & Bovee, J.V.M.G. (2013), Radiation Induced Sarcomas Occurring in Desmoid-Type Fibromatosis Are Not Derived from the Primary Tumour, Laboratory Investigation 93: 11A-11A.
- Cleton-Jansen, A.M.; Wijers-Koster, P.M.; Coffin, C.M.; Rubin, B.P. & Bovee, J.V.M.G. (2013), Radiation Induced Sarcomas Occurring in Desmoid-Type Fibromatosis Are Not Derived from the Primary Tumour, Modern Pathology 26: 11A-11A.
- Oosterwijk, J.G. van; Meijer, D.; Ruler, M.A.J.H. van; Akker, B.E.W.M. van den; Oosting, J.; Krenacs, T.; Picci, P.; Flanagan, A.M.; Liegl-Atzwanger, B.; Leithner, A.; Athanasou, N.; Daugaard, S.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2013), Screening for Potential Targets for Therapy in Mesenchymal, Clear Cell, and Dedifferentiated Chondrosarcoma Reveals Bcl-2 Family Members and TGF beta as Potential Targets, American Journal of Pathology 182(4): 1347-1356.
- Oosterwijk, J.G. van; Ruler, M.A.J.H. van; Briaire-de Bruijn, I.H.; Herpers, B.; Gelderblom, H.; Water, B. van de & Bovee, J.V.M.G. (2013), Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells, British Journal of Cancer 109(5): 1214-1222.
- Hughes, L.A.E.; Melotte, V.; Schrijver, J. de; Maat, M. de; Smit, V.T.H.B.M.; Bovee, J.V.M.G.; French, P.J.; Brandt, P.A. van den; Schouten, L.J.; Meyer, T. de; Criekinge, W. van; Ahuja, N.; Herman, J.G.; Weijenberg, M.P. & Engeland, M. van (2013), The CpG Island Methylator Phenotype: What's in a Name?, Cancer Research 73(19): 5858-5868.
- Oosterwijk, J.G. van; Anninga, J.K.; Gelderblom, H.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2013), Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma, Hematology/Oncology Clinics of North America 27(5): 1021-1048.
- Solomon, D.A.; Kim, J.S.; Bondaruk, J.; Shariat, S.F.; Wang, Z.F.; Elkahloun, A.G.; Ozawa, T.; Gerard, J.; Zhuang, D.Z.; Zhang, S.Z.; Navai, N.; Siefker-Radtke, A.; Phillips, J.J.; Robinson, B.D.; Rubin, M.A.; Volkmer, B.; Hautmann, R.; Kufer, R.; Hogendoorn, P.C.W.; Netto, G.; Theodorescu, D.; James, C.D.; Czerniak, B.; Miettinen, M. & Waldman, T. (2013), Frequent truncating mutations of STAG2 in bladder cancer, Nature Genetics 45(12): 1428-U171.
- Graaff, M.A. de; Szuhai, K.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2013), MED12 Exon 2 Mutation Analysis in Different Subtypes of Smooth Muscle Tumors Confirms Genetic Heterogeneity.
- Graaff, M.A. de; Szuhai, K.; Cleton-Jansen, A.M. & Bovee, J.V.M.G. (2013), MED12 Exon 2 Mutation Analysis in Different Subtypes of Smooth Muscle Tumors Confirms Genetic Heterogeneity.
- Verbeke, S.L.J.; Bertoni, F.; Bacchini, P.; Oosting, J.; Sciot, R.; Krenacs, T.; Dijke, P. ten & Bovee, J.V.M.G. (2013), Active TGF-beta Signalling and Decreased Expression of PTEN Separates Angiosarcoma of Bone from Its Soft Tissue Counterpart.
- Verbeke, S.L.J.; Bertoni, F.; Bacchini, P.; Oosting, J.; Sciot, R.; Krenacs, T.; Dijke, P. ten & Bovee, J.V.M.G. (2013), Active TGF-beta Signalling and Decreased Expression of PTEN Separates Angiosarcoma of Bone from Its Soft Tissue Counterpart.
- Flucke, U.; Tops, B.B.J.; Verdijk, M.A.J.; Cleef, P.J.H. van; Zwam, P.H. van; Slootweg, P.J.; Bovee, J.V.M.G.; Riedl, R.G.; Creytens, D.H.; Suurmeijer, A.J.H. & Mentzel, T. (2012), NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma, Virchows Archiv 460(6): 621-628.
- Wang, L.; Motoi, T.; Khanin, R.; Olshen, A.; Mertens, F.; Bridge, J.; Cin, P. dal; Antonescu, C.R.; Singer, S.; Hameed, M.; Bovee, J.V.M.G.; Hogendoorn, P.C.W.; Socci, N. & Ladanyi, M. (2012), Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data, Genes, Chromosomes and Cancer 51(2): 127-139.
- Andrea, C.E. de; Wiweger, M.I.; Bovee, J.V.M.G.; Romeo, S. & Hogendoorn, P.C.W. (2012), Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation, Virchows Archiv 460(1): 95-102.
- Hollmann, T.J.; Bovee, J.V.M.G. & Fletcher, C.D.M. (2012), Digital Fibromyxoma (Superficial Acral Fibromyxoma): A Detailed Characterization of 124 Cases, American Journal of Surgical Pathology 36(6): 789-798.
- Wang, W.L.; Evans, H.L.; Meis, J.M.; Liegl-Atzwanger, B.; Bovee, J.V.M.G.; Goldblum, J.R.; Billings, S.D.; Rubin, B.P.; Lopez-Terrada, D. & Lazar, A.J. (2012), FUS rearrangements are rare in 'pure' sclerosing epithelioid fibrosarcoma.
- Demicco, E.G.; Torres, K.E.; Ghadimi, M.P.; Colombo, C.; Bolshakov, S.; Hoffman, A.; Peng, T.S.; Bovee, J.V.M.G.; Wang, W.L.; Lev, D. & Lazar, A.J. (2012), Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
- Szuhai, K.; Cleton-Jansen, A.M.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2012), Molecular pathology and its diagnostic use in bone tumors, Cancer Genetics 205(5): 193-204.
- Meijer, D.; Jong, D. de; Pansuriya, T.C.; Akker, B.E. van den; Picci, P.; Szuhai, K. & Bovee, J.V.G.M. (2012), Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma, Genes, Chromosomes and Cancer 51(10): 899-909.
- Oosterwijk, J.G. van; Jong, D. de; Ruler, M.A.J.H. van; Hogendoorn, P.C.W.; Dijkstra, P.D.S.; Rijswijk, C.S.P. van; Machado, I.; Llombart-Bosch, A.; Szuhai, K. & Bovee, J.V.M.G. (2012), Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone, BMC Cancer 12: -.
- Andrea, C.E. de; Reijnders, C.M.A.; Kroon, H.M.; Jong, D. de; Hogendoorn, P.C.W.; Szuhai, K. & Bovee, J.V.M.G. (2012), Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT, Oncogene 31(9): 1095-1104.
- Andrea, C.E. de; Kroon, H.M.; Wolterbeek, R.; Romeo, S.; Rosenbeig, A.E.; DeYoung, B.R.; Liegl-Atzwanger, B.; Inwards, C.Y.; Hauben, E.; McCarthy, E.; Idoate, M.; Athanason, N.A.; Jones, K.B.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2012), Interobserver Reliability in the Histopathological Diagnosis of Peripheral Cartilaginous Tumors in Patients with Multiple Osteochondromas: How Can We Improve Diagnostic Quality?
- Andrea, C.E. de; Kroon, H.M.; Wolterbeck, R.; Romeo, S.; Rosenberg, A.E.; DeYoung, B.R.; Liegl-Alzwanger, B.; Inwards, C.Y.; Hauben, E.; McCarthy, E.F.; Idoate, M.; Athanasou, N.A.; Jones, K.B.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2012), Interobserver Reliability in the Histopathological Diagnosis of Peripheral Cartilaginous Tumors in Patients with Multiple Osteochondromas: How Can We Improve Diagnostic Quality?
- Bos, S.D.; Bovee, J.V.M.G.; Duijnisveld, B.J.; Raine, E.V.A.; Dalen, W.J.; Ramos, Y.F.M.; Breggen, R. van der; Nelissen, R.G.H.H.; Slagboom, P.E.; Loughlin, J. & Meulenbelt, I. (2012), Increased type II deiodinase protein in OA-affected cartilage and allelic imbalance of OA risk polymorphism rs225014 at DIO2 in human OA joint tissues., Annals of the Rheumatic Diseases 71(7): 1254-8.
- Waaijer, C.J.F.; Andrea, C.E. de; Hamilton, A.; Oosterwijk, J.G. van; Stringer, S.E. & Bovee, J.V.M.G. (2012), Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes, Virchows Archiv 461(4): 475-481.
- Andrea, C.E. de; Kroon, H.M.; Wolterbeek, R.; Romeo, S.; Rosenberg, A.E.; Young, B.R. de; Liegl, B.; Inwards, C.Y.; Hauben, E.; McCarthy, E.F.; Idoate, M.; Athanasou, N.A.; Jones, K.B.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2012), Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas, Modern Pathology 25(9): 1275-1283.
- Boeuf, S.; Bovee, J.V.M.G.; Lehner, B.; Akker, B. van den; Ruler, M. van; Cleton-Jansen, A.M. & Richter, W. (2012), BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors, BMC Cancer 12: -.
- Oosterwijk, J.G. van; Herpers, B.; Meijer, D.; Briaire-de Bruijn, I.H.; Cleton-Jansen, A.M.; Gelderblom, H.; Water, B. van de & Bovee, J.V.M.G. (2012), Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance, Annals of Oncology 23(6): 1617-+.
- Romeo, S.; Bovee, J.V.M.G.; Kroon, H.M.; Tirabosco, R.; Natali, C.; Zanatta, L.; Sciot, R.; Mertens, F.; Athanasou, N.; Alberghini, M.; Szuhai, K.; Hogendoorn, P.C.W. & Tos, A.P.D. (2012), Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches, Virchows Archiv 461(5): 561-570.
- Meijer, D.; Gelderblom, H.; Karperien, M.; Cleton-Jansen, A.M.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2011), Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo, Clinical Sarcoma Research 1.
- Mertens, F.; Romeo, S.; Bovee, J.V.M.G.; Tirabosco, R.; Athanasou, N.; Alberghini, M.; Hogendoorn, P.C.W.; Tos, A.P.D.; Sciot, R.; Domanski, H.A.; Astrom, K.; Mandahl, N. & Debiec-Rychter, M. (2011), Reclassification and subtyping of so-called malignant fibrous histiocytoma of bone: comparison with cytogenetic features, Clinical Sarcoma Research 1.
- Pansuriya, T.C.; Oosting, J.; Verdegaal, S.H.M.; Flanagan, A.M.; Sciot, R.; Kindblom, L.G.; Hogendoorn, P.C.W.; Szuhai, K. & Bovee, J.V.M.G. (2011), Maffucci Syndrome: A Genome-Wide Analysis Using High Resolution Single Nucleotide Polymorphism and Expression Arrays on Four Cases, Genes, Chromosomes and Cancer 50(9): 673-679.
- Bowen, M.E.; Boyden, E.D.; Holm, I.A.; Campos-Xavier, B.; Bonafe, L.; Superti-Furga, A.; Ikegawa, S.; Cormier-Daire, V.; Bovee, J.V.; Pansuriya, T.C.; Sousa, S.B. de; Savarirayan, R.; Andreucci, E.; Vikkula, M.; Garavelli, L.; Pottinger, C.; Ogino, T.; Sakai, A.; Regazzoni, B.M.; Wuyts, W.; Sangiorgi, L.; Pedrini, E.; Zhu, M.; Kozakewich, H.P.; Kasser, J.R.; Seidman, J.G.; Kurek, K.C. & Warman, M.L. (2011), Loss-of-Function Mutations in PTPN11 Cause Metachondromatosis, but Not Ollier Disease or Maffucci Syndrome, PLoS Genetics 7(4): -.
- Szuhai, K.; Jennes, I.; Jong, D. de; Bovee, J.V.M.G.; Wiweger, M.; Wuyts, W. & Hogendoorn, P.C.W. (2011), Tiling Resolution Array-CGH Shows That Somatic Mosaic Deletion of the EXT Gene is Causative in EXT Gene Mutation Negative Multiple Osteochondromas Patients, Human Mutation 32(2): E2036-E2049.
- Jones, E.A.; Remoortere, A. van; Zeijl, R.J.M. van; Hogendoorn, P.C.W.; Bovee, J.V.M.G.; Deelder, A.M. & McDonnell, L.A. (2011), Multiple Statistical Analysis Techniques Corroborate Intratumor Heterogeneity in Imaging Mass Spectrometry Datasets of Myxofibrosarcoma, PLoS ONE 6(9): -.
- Pansuriya, T.C.; Oosting, J.; Krenacs, T.; Taminiau, A.H.M.; Verdegaal, S.H.M.; Sangiorgi, L.; Sciot, R.; Hogendoorn, P.C.W.; Szuhai, K. & Bovee, J.V.M.G. (2011), Genome-wide analysis of Ollier disease: Is it all in the genes?, Orphanet Journal of Rare Diseases 6.
- Verdegaal, S.H.M.; Bovee, J.V.M.G.; Pansuriya, T.C.; Grimer, R.J.; Ozger, H.; Jutte, P.C.; San Julian, M.; Biau, D.J.; Geest, I.C.M. van der; Leithner, A.; Streitburger, A.; Klenke, F.M.; Gouin, F.G.; Campanacci, D.A.; Marec-Berard, P.; Hogendoorn, P.C.W.; Brand, R. & Taminiau, A.H.M. (2011), Incidence, predictive factors, and prognosis of chondrosarcoma in patients with ollier disease and maffucci syndrome: an international multicenter study of 161 patients., The Oncologist 16(12): 1771-9.
- Verbeke, S.L.J.; Bertoni, F.; Bacchini, P.; Sciot, R.; Fletcher, C.D.M.; Kroon, H.M.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2011), Distinct histological features characterize primary angiosarcoma of bone, Histopathology 58(2): 254-264.
- Verbeke, S.L.J. & Bovee, J.V.M.G. (2011), Primary vascular tumors of bone: a spectrum of entities?, International Journal of Clinical and Experimental Pathology 4(6): 541-551.
- Thunnissen, E.; Bovee, J.V.M.G.; Bruinsma, H.; Brule, A.J.C. van den; Dinjens, W.; Heideman, D.A.M.; Meulemans, E.; Nederlof, P.; Noesel, C. van; Prinsen, C.F.M.; Scheidel, K.; Ven, P.M. van de; Weger, R. de; Schuuring, E. & Ligtenberg, M. (2011), EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy, Journal of Clinical Pathology 64(10): 884-892.
- Olsson, L.; Paulsson, K.; Bovee, J.V.M.G. & Nord, K.H. (2011), Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma, PLoS ONE 6(9): -.
- Vermaat, M.; Vanel, D.; Kroon, H.M.; Verbeke, S.L.J.; Alberghini, M.; Bovee, J.V.M.G. & Bloem, J.L. (2011), Vascular tumors of bone: Imaging findings, European Journal of Radiology 77(1): 13-18.
- Taminiau AHM, Bovee JVMG, van Rijswijk CSP, Gelderblom HAJ & van de Sande MAJ (2011), Cartilage - Forming Bone Tumours, EUROPEAN INSTRUCTIONAL LECTURES, VOL 11 11: 23-44.
- Pansuriya, T.C.; Eijk, R. van; d'Adamo, P.; Ruler, M.A.J.H. van; Kuijjer, M.L.; Oosting, J.; Cleton-Jansen, A.M.; Oosterwijk, J.G. van; Verbeke, S.L.J.; Meijer, D.; Wezel, T. van; Nord, K.H.; Sangiorgi, L.; Toker, B.; Liegl-Atzwanger, B.; San-Julian, M.; Sciot, R.; Limaye, N.; Kindblom, L.G.; Daugaard, S.; Godfraind, C.; Boon, L.M.; Vikkula, M.; Kurek, K.C.; Szuhai, K.; French, P.J. & Bovee, J.V.M.G. (2011), Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome, Nature Genetics 43(12): 1256-U124.
- Bovee, J.V.M.G. (2010), EXTra hit for mouse osteochondroma, Proceedings of the National Academy of Sciences 107(5): 1813-1814.
- de Andrea CE, Wiweger M, Bovee JVMG, Romeo S & Hogendoorn PCW (2010), Primary Cilia Organization Orchestrating Cell Polarity in the Growth Plate and Its Loss in Osteochondroma, Laboratory Investigation 90: 18A18A.
- Andrea, C.E. de; Wiweger, M.; Bovee, J.V.M.G.; Romeo, S. & Hogendoorn, P.C.W. (2010), Primary Cilia Organization Orchestrating Cell Polarity in the Growth Plate and Its Loss in Osteochondroma, Modern Pathology 23: 18A18A.
- Andrea, C.E. de; Wiweger, M.; Prins, F.; Bovee, J.V.M.G.; Romeo, S. & Hogendoorn, P.C.W. (2010), Primary cilia organization reflects polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma, Laboratory Investigation 90(7): 1091-1101.
- Dornauer, K.; Soder, S.; Inwards, C.Y.; Bovee, J.V.M.G. & Aigner, T. (2010), Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas, Pathology International 60(5): 365-372.
- Bovee, J.V.M.G. & Hogendoorn, P.C.W. (2010), Molecular pathology of sarcomas: concepts and clinical implications, Virchows Archiv 456(2): 193-199.
- Reijnders, C.M.A.; Waaijer, C.J.F.; Hamilton, A.; Buddingh, E.; Dijkstra, P.D.S.; Ham, S.J.; Bakker, E.; Szuhai, K.; Karperien, M.; Hogendoorn, P.C.W.; Stringer, S.E. & Bovee, J.V.M.G. (2010), Osteochondroma Formation: Haploinsufficiency or Two Hits?, Laboratory Investigation 90: 26A26A.
- Reijnders, C.M.A.; Waaijer, C.J.F.; Hamilton, A.; Buddingh, E.; Dijkstra, P.D.S.; Ham, S.J.; Bakker, E.; Szuhai, K.; Karperien, M.; Hogendoorn, P.C.W.; Stringer, S.E. & Bovee, J.V.M.G. (2010), Osteochondroma Formation: Haploinsufficiency or Two Hits?, Modern Pathology 23: 26A26A.
- Schrage, Y.M.; Machado, I.; Meijer, D.; Briaire-de Bruijn, I.; Akker, B.E. van den; Taminiau, A.H.M.; Kalinski, T.; Llombart-Bosch, A. & Bovee, J.V.M.G. (2010), COX-2 expression in chondrosarcoma: A role for celecoxib treatment?, European Journal of Cancer 46(3): 616-624.
- Verbeke, S.L.J.; Fletcher, C.D.M.; Alberghini, M.; Daugaard, S.; Flanagan, A.M.; Parratt, T.; Kroon, H.M.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2010), A Reappraisal of Hemangiopericytoma of Bone; Analysis of Cases Reclassified as Synovial Sarcoma and Solitary Fibrous Tumor of Bone, American Journal of Surgical Pathology 34(6): 777-783.
- Boeuf, S.; Bovee, J.V.M.G.; Lehner, B.; Hogendoorn, P.C.W. & Richter, W. (2010), Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours, Histopathology 56(5): 641-651.
- Pansuriya, T.C.; Kroon, H.M. & Bovee, J.V.M.G. (2010), Enchondromatosis: insights on the different subtypes, International Journal of Clinical and Experimental Pathology 3(6): 557-569.
- Reijnders, C.M.A.; Waaijer, C.J.F.; Hamilton, A.; Buddingh, E.P.; Dijkstra, S.P.D.; Ham, J.; Bakker, E.; Szuhai, K.; Karperien, M.; Hogendoorn, P.C.W.; Stringer, S.E. & Bovee, J.V.M.G. (2010), No Haploinsufficiency but Loss of Heterozygosity for EXT in Multiple Osteochondromas, American Journal of Pathology 177(4): 1946-1957.
- Bovee, J.V.M.G.; Hogendoorn, P.C.W.; Wunder, J.S. & Alman, B.A. (2010), Cartilage tumours and bone development: molecular pathology and possible therapeutic targets, Nature Reviews Cancer 10(7): 481-488.
- Diaz-Romero, J.; Romeo, S.; Bovee, J.V.M.G.; Hogendoorn, P.C.W.; Heini, P.F. & Mainil-Varlet, P. (2010), Hierarchical Clustering of Flow Cytometry Data for the Study of Conventional Central Chondrosarcoma, Journal of Cellular Physiology 225(2): 601-611.
- Willems, S.M.; Schrage, Y.M.; Briaire-de Bruijn, I.H.; Szuhai, K.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2010), Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option, Molecular Cancer 9.
- Eefting D, Schrage YM, Geirnaerdt MJA, Le Cessie S, Taminiau AHM, Bovee JVMG & Hogendoorn PCW (2009), Assessment of Interobserver Variability and Histologic Parameters to Improve Reliability in Classification and Grading of Central Cartilaginous Tumors, American Journal of Surgical Pathology 33(1): 50-57.
- van de Luijtgaarden ACM, Veth RPH, Slootweg PJ, Wijers-Koster PM, Kool LJS, Bovee JVMG & van der Graaf WTA (2009), Metastatic potential of an aneurysmal bone cyst, Virchows Archiv 455(5): 455-459.
- Reijnders, C.M.A.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2009), The molecular and cellular basis exostosis formation in hereditary multiple exostoses, International Journal of Experimental Pathology 90(2): 190-191.
- Schrage, Y.M.; Briaire-de Bruijn, I.H.; Miranda, N.F.C.C. de; Oosterwijk, J. van; Taminiau, A.H.M.; Wezel, T. van; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2009), Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for Treatment, Cancer Research 69(15): 6216-6222.
- Hallor, K.H.; Staaf, J.; Bovee, J.V.M.G.; Hogendoorn, P.C.W.; Cleton-Jansen, A.M.; Knuutila, S.; Savola, S.; Niini, T.; Brosjo, O.; Bauer, H.C.F.; Steyern, F.V. von; Jonsson, K.; Skorpil, M.; Mandahl, N. & Mertens, F. (2009), Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors, Clinical Cancer Research 15(8): 2685-2694.
- Rozeman, L.B.; Bruijn, I.H.B. de; Bacchini, P.; Staals, E.L.; Bertoni, F.; Bovee, J.V.M.G. & Hogendoorn, P.C.W. (2009), Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes, Modern Pathology 22(11): 1489-1498.
- Schrage, Y.M.; Hameetman, L.; Szuhai, K.; Cleton-Jansen, A.M.; Taminiau, A.H.M.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2009), Aberrant Heparan Sulfate Proteoglycan Localization, Despite Normal Exostosin, in Central Chondrosarcoma, American Journal of Pathology 174(3): 979-988.
- Kroep JR, Bovee JVMG, van der Molen AJ, Hogendoorn PCW & Gelderblom H (2009), Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature, Journal of Cutaneous Pathology 36(5): 565-569.
- Verbeke, S.L.; Bertoni, F.; Bacchini, P.; Sciot, R.; Mertens, B.J.; Kroon, H.M.; Hogendoora, P.C. & Bovee, J.V. (2009), Hemangioendothelioma and Angiosarcoma of Bone: Distinct Histological Criteria Predicting Clinical Behavior, Modern Pathology 22: 24A24A.
- Verbeke SL, Bertoni F, Bacchini P, Sciot R, Mertens BJ, Kroon HM, Hogendoorn PC & Bovee JV (2009), Hemangioendothelioma and Angiosarcoma of Bone: Distinct Histological Criteria Predicting Clinical Behavior, Laboratory Investigation 89: 24A24A.
- Verbeke SL, Fletcher CD, Picci P, Daugaard S, Kroon HM, Hogendoorn PC & Bovee JV (2009), Haemangiopericytoma of Bone: Real or Imagined?, Modern Pathology 22: 24A25A.
- LVerbeke S, Fletcher CD, Picci P, Daugaard S, Kroon HM, Hogendoorn PC & Bovee JV (2009), Haemangiopericytoma of Bone: Real or Imagined?, Laboratory Investigation 89: 24A25A.
- Szuhai K, de Jong J, Bovee JVMG, Jennes I, Wuyts W, Wiweger M, Tanke HJ & Hogendoorn PCW (2009), Somatic Mosaicism Is Causative in EXT1/2 Negative Multiple Osteochondroma Detected by Tiling Resolution Array-CGH, Modern Pathology 22: 23A23A.
- Szuhai K, de Jong J, Bovee JVMG, Jennes I, Wuyts W, Wiweger M, Tanke HJ & Hogendoorn PCW (2009), Somatic Mosaicism Is Causative in EXT1/2 Negative Multiple Osteochondroma Detected by Tiling Resolution Array-CGH, Laboratory Investigation 89: 23A23A.
- Schrage, Y.M.; Lam, S.; Jochemsen, A.G.; Cleton-Jansen, A.M.; Taminiau, A.H.M.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2009), Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro, Journal of Cellular and Molecular Medicine 13(9A): 2843-2852.
- Gelderblom H, Hogendoorn PCW, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AHM & Bovee JVMG (2008), The clinical approach towards chondrosarcoma, Oncologist 13(3).
- Boeuf S, Kunz P, Hennig T, Lehner B, Hogendoorn PCW, Bovee JVMG & Richter W (2008), A chondrogenic gene expression signature in mesenchymal stem cells is a classifier of conventional central chondrosarcoma, Journal of Pathology 216(2).
- Bovee JV (2008), Multiple osteochondromas, Orphanet Journal of Rare Diseases 3.
- Zwaga T, Bovee JVMG & Kroon HM (2008), Best cases from the AFIP - Osteosarcoma of the femur with skip, lymph node, and lung metastases, Radiographics 28(1).
- Willems SM, Schrage YM, Baelde JJ, Bruijn IBD, Mohseny A, Sciot R, Bovee JVMG & Hogendoorn PCW (2008), Myxoid tumours of soft tissue: the so-called myxoid extracellular matrix is heterogeneous in composition, Histopathology 52(4).
- Verbeke SLJ, Bacchini P, Kroon HMH, Hogendoorn PCW & Bovee JVMG (2007), Primary malignant vascular tumours of bone: Immunohistochemical investigation on endothelial phenotype and histopathological correlation, Virchows Archiv 451(2): 151-152.
- Bovee JVMG (2007), Chondrosarcoma subtyping: a hobby for the pathologist or important to find therapeutic targets?, EJC Supplements 5(4): 40-40.
- Bovee JVMG (2007), Contribution of pathology to decision-making in retroperitoneal sarcoma, EJC Supplements 5(4): 9-9.
- Willems S, Schrage Y, Baelde H, Mohseny A, Sciot R, Bovee J & Hogendoorn P (2007), Myxoid soft tissue tumours have a heterogeneous composition of their extracellular matrix: A study on myxofibrosarcoma, intramuscular myxoma and extraskeletal myxoid chondrosarcoma, Virchows Archiv 451(2): 149-149.
- Romeo S, Oosting J, Rozeman LB, Hameetman L, Taminiau AHM, Cleton-Jansen AM, Bovee JVMG & Hogendoorn PCW (2007), The role of noncartilage-specific molecules in differentiation of cartilaginous tumors - Lessons from chondroblastoma and chondromyxoid fibroma, Cancer 110(2).
- Hameetman, L.; Szuhai, K.; Yavas, A.; Knijnenburg, J.; Duin, M. van; Dekken, H. van; Taminiau, A.H.M.; Cleton-Jansen, A.M.; Bovee, J.V.M.G. & Hogendoorn, P.C.W. (2007), The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions, Journal of the National Cancer Institute 99(5).
- Schrage YM, Hameetman L, Szuhai K, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW & Bovee JVMG (2007), EXT and its downstream targets in central chondrosarcoma (CCS), Modern Pathology 20.
- Schrage YM, Hameetman L, Szuhai K, Cleton-Jansen AM, Taminian AHM, Hogendoorn PCW & Bovee JVMG (2007), EXT and its downstream targets in central chondrosarcoma (CCS), Laboratory Investigation 87.
- Willems SM, Szuhai K, Hartgrink H, Bovee JVMG, De Schepper A & Hogendoorn PCW (2007), CT-guided, COBRA-FISH-assisted diagnosis of well-differentiated liposarcoma (inflammatory subtype) of the retroperitoneum, Histopathology 51(3).
- Hameetman L, David G, Yavas A, White SJ, Taminiau AHM, Cleton-Jansen AM, Hogendoorn PCW & Bovee JVMG (2007), Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas, Journal of Pathology 211(4).
- Schrage YM, Szuhai K, Taminian AHM, Hogendoorn PCW & Bovee JVMG (2006), CDK4 amplification in central chondrosarcoma is associated with tumor progression, Modern Pathology 19: 18A18A.
- Schrage YM, Szuhai K, Taminiau AHM, Hogendoorn PCW & Bovee JVMG (2006), CDK4 amplification in central chondrosarcoma is associated with tumor progression, Laboratory Investigation 86: 18A18A.
- Rozeman, L.B.; Szuhai, K.; Schrage, Y.M.; Rosenberg, C.; Tanke, H.J.; Taminiau, A.H.M.; Cleton-Jansen, A.M.; Bovee, J.V.M.G. & Hogendoorn, P.C.W. (2006), Array-comparative genomic hybridization of central chondrosarcoma - Identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations, Cancer 107(2).
- Romeo S, Hameetman L, Oosting J, Rozeman LB, Cleton-Jansen AM, Bovee JVMG & Hogendoorn PCW (2006), A differentially expressed gene-set differentiates chondromyxoid fibroma from high-grade central chondrosarcoma, Laboratory Investigation 86: 17A17A.
- Romeo S, Hameetman L, Oosting J, Rozeman LB, Cleton-Jansen AM, Bovee JVMG & Hogendoorn PCW (2006), A differentially expressed gene-set differentiates chondromyxoid fibroma from high-grade central chondrosarcoma, Modern Pathology 19: 17A17A.
- Bovee, J.; Hameetman, L.; Kroon, H.M.; Aigner, T. & Hogendoom, P.C.W. (2006), EXT-related pathways are not involved in the pathogenesis of dysplasia epiphysealis hemimelica and metachondromatosis, The Journal of Pathology 209(3).
- Hameetman, L.; Rozeman, L.B.; Lombaerts, M.; Oostlng, J.; Taminiau, A.H.M.; Cleton-Jansen, A.M.; Bovee, J.V.M.G. & Hogendoom, P.C.W. (2006), Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling, The Journal of Pathology 209(4).
- Hameetman L, Cleton-Jansen AM, Rozeman LB, Lombaerts M, Taminiau AHM, Bovee JVMG & Hogendoorn PCW (2005), Progression of secondary peripheral chondrosarcoma is characterized by downregulation of oxidative phosphrylation genes, Modern Pathology 18: 15A15A.
- Hameetman L, Cleton-Jansen AM, Rozeman LB, Lombaerts M, Taminiau AHM, Bovee JVMG & Hogendoorn P (2005), Progression of secondary peripheral chondrosarcoma is characterized by downregulation of oxidative phosphrylation genes, Laboratory Investigation 85: 15A15A.
- Romeo S, Bovee JVMG, Grogan SP, Taminiau AH, Eilers PHC, Cleton-Jansen AM, Mainil-Varlet P & Hogendoorn PCW (2005), Chondromyxoid fibroma resembles in vitro chondrogenesis, but differs in expression of signalling molecules, Journal of Pathology 206(2).
- Hameetman L, Hogendoorn PCW, Kroon HM, Aigner T & Bovee JVMG (2005), EXT-Related pathways are not involved in pathogenesis of dysplasia epiphysealis hemimelica and metachondromatosis, Laboratory Investigation 85.
- Hameetman L, Hogendoorn PCW, Kroon HM, Aigner T & Bovee JVMG (2005), EXT-related pathways are not involved in pathogenesis of dysplasia epiphysealis hemimelica and metachondromatosis, Modern Pathology 18.
- Hameetman L, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW & Bovee JVMG (2005), Loss of EXT Expression causes downregulation of IHh signaling in hereditary and solitary osteochondromas, Modern Pathology 18: 15A15A.
- Rozeman LB, Szuhai K, Bovee JVMG, Rosenberg C, Tanke HJ & Hogendoorn PCW (2005), Arrary-CGH analysis of conventional central chondrosarcomas points to chromosome 6 and 12 involvement in tumor progression, Modern Pathology 18: 21A21A.
- Hameetman L, Kok P, Eilers PHC, Cleton-Jansen AM, Hogendoorn PCW & Bovee JVMG (2005), The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting, Virchows Archiv 446(4).
- Rozeman LB, Hameetman L, van Wezel T, Cleton-Jansen AM, Hogendoorn PCW & Bovee JVMG (2005), cDNA microarray analysis of conventional central chondrosarcomas identifies genes associated with tumor progression, not related to Ollier disease, Modern Pathology 18: 21A22A.
- Cleton-Jansen, A.M.; Beerendonk, H.M. van; Baelde, H.J.; Bovee, J.V.G.M.; Karperien, M. & Hogendoorn, P.C.W. (2005), Estrogen signaling is active in cartilaginous tumors: Implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma, Clinical Cancer Research 11(22).
- Rozeman LB, Hameetman L, van Wezel T, Taminiau AHM, Cleton-Jansen AM, Hogendoorn PCW & Bovee JVMG (2005), cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade, Journal of Pathology 207(1).
- Bovee JVMG, Cleton-Jansen AM, Taminiau AHM & Hogendoorn PCW (2005), Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment, Lancet Oncology 6(8).
- Rozeman, L.B.; Hameetman, L.; Cleton-Jansen, A.M.; Taminiau, A.H.M.; Hogendoorn, P.C. & Bovee, J.V.M.G. (2005), Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas, Journal of Pathology 205(4).
- Rozeman LB, Hameetman L, van Wezel T, Cleton-Jansen AM, Hogendoorn PCW & Bovee JVMG (2005), cDNA microarray analysis of conventional central chondrosarcomas identifies genes associated with tumor progression, not related to Ollier disease, Laboratory Investigation 85: 21A22A.
- Rozeman LB, Szuhai K, Bovee JVMG, Rosenberg C, Tanke HJ & Hogendoorn PCW (2005), Array-CGH analysis of conventional central chondrosarcomas points to chromosome 6 and 12 involvement in tumor progression, Laboratory Investigation 85: 21A21A.
- Hameetman L, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW & Bovee JVMG (2005), Loss of EXTExpression causes downregulation of IHh signaling in hereditary and solitary osteochondromas, Laboratory Investigation 85: 15A15A.
- Cleton-Jansen AM, Van Beerendonk HM, Bovee JV, Szuhai K, Karperien M & Hogendoorn PC (2005), Estrogen signaling is active in chondrosarcoma; Implications for anti-estrogens as treatment of chondrosarcoma, Modern Pathology 18: 12A12A.
- Ropero S, Setien F, Espada J, Fraga MF, Herranz M, Asp J, Benassi MS, Franchi A, Patino A, Ward LS, Bovee J, Cigudosa JC, Wim W & Esteller M (2004), Epigenetic loss of the familial tumor-suppressor gene exostosin-1 (EXT1) disrupts heparan sulfate synthesis in cancer cells, Human Molecular Genetics 13(22).
- van Beerendonk HM, Rozeman LB, Taminiau AH, Sciot R, Bovee JVMG, Cleton-Jansen AM & Hogendoorn PC (2004), Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression, Journal of Pathology 202(3).
- Romeo S, Bovee JVMG, Jadnanansing NAA, Taminiau AHM & Hogendoorn PCW (2004), Expression of cartilage growth plate signalling molecules in chondroblastoma, Journal of Pathology 202(1).
- Rozeman, L.B.; Sangiorgi, L.; Briaire-de Bruijn, I.H.; Mainil-Varlet, P.; Bertoni, F.; Cleton-Jansen, A.M.; Hogendoorn, P.C.W. & Bovee, J.V.M.G. (2004), Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C, Human Mutation 24(6).
- Kok P, Hogendoorn PCW, van den Broek LJCM & Bovee JVMG (2002), Bcl-2 expression as a diagnostic marker to identify malignant progression of osteochondroma, Modern Pathology 15(1): 17A17A.
- Bovee, J.V.M.G.; Sakkers, R.J.B.; Geirnaerdt, M.J.A.; Taminiau, A.H.M. & Hogendoorn, P.C.W. (2002), Intermediate grade osteosarcoma and chondrosarcoma arising in an osteochondroma. A case report of a patient with hereditary multiple exostoses, Journal of Clinical Pathology 55(3).
- Kok P, Hogendoorn PCW, van den Broek LJCM & Bovee JVMG (2002), Bcl-2 expression as a diagnostic marker to identify malignant progression of osteochondroma, Laboratory Investigation 82(1): 17A17A.
- Bovee JVMG, van den Broek LJCM, Cleton-Jansen AM & Hogendoorn PCW (2001), Upregulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma, Journal of Pathology 193: 1A1A.
- Bovee, J.V.M.G.; Broek, L.J.C.M. van den; Cleton-Jansen, A.M. & Hogendoom, P.C.W. (2001), Chondrosarcoma is not characterized by detectable telomerase activity, The Journal of Pathology 193(3).
- Bovee JVMG, Sciot R, Cin PD, Debiec-Rychter M, van Zelderen-Bhola SL, Cornelisse CJ & Hogendoorn PCW (2001), Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: A cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes, Diagnostic Molecular Pathology 10(4).
- Baelde, H.J.; Cleton-Jansen, A.M.; Beerendonk, H. van; Namba, M.; Bovee, J.V.M.G. & Hogendoorn, P.C.W. (2001), High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma, Journal of Clinical Pathology 54(10).
- Bovee JVMG, van Roggen JFG, Cleton-Jansen AM, Taminiau AHM, van der Woude HJ & Hogendoorn PCW (2000), Malignant progression in multiple enchondromatosis (Ollier's disease): An autopsy-based molecular genetic study, Human Pathology 31(10).
- Bovee, J.V.M.G.; Broek, L.J.C.M. van den; Cleton-Jansen, A.M. & Hogendoorn, P.C.W. (2000), Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma, Laboratory Investigation 80(12).
- van Roggen JF, Bovee JVMG, van der Woude HJ & Hogendoorn PCW (2000), An update of diagnostic strategies using molecular genetic and magnetic resonance imaging techniques for musculoskeletal tumors.
- Bovee, J.V.M.G. & Hogendoorn, P.C.W. (2000), Re. Review Article entitled 'The neoplastic pathogenesis of solitary and multiple osteochondromas'.
- Bovee, J.V.M.G.; Royen, M. van; Bardoel, A.F.J.; Rosenberg, C.; Cornelisse, C.J.; Cleton-Jansen, A.M. & Hogendoorn, P.C.W. (2000), Near-haploidy and subsequent polyploidization characterize the progression of peripheral chondrosarcoma, American Journal of Pathology 157(5).